Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and metaanalysis of randomized controlled trials.

David J. Sullivan, Daniele Focosi, Daniel F. Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth

Corresponding author: David Sullivan, 615 N. Wolfe St Rm W4606, Baltimore MD 21205. Tel 410 502 2522, fax 410 955 0105. E-mail dsulliv7@jhmi.edu.

Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD USA (Prof. D J Sullivan M.D., Prof. A Casadevall M.D.PhD,); North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy (Prof. D Focosi, M.D.); Johns Hopkins University School of Medicine Department of Neurology, Brain Injury Outcomes Division, Baltimore, MD, USA (Prof. D F Hanley M.D., J Ou M.S.); Division of Hematology, Carlo Poma Hospital, Mantua, Italy (Prof. M Cruciani M.D., Prof. M Franchini M.D.,); Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA (Prof. N Paneth, M.D., M.P.H)

Keywords: small molecule antivirals; convalescent plasma; monoclonal antibody; COVID-19; outpatients; randomized controlled trial.

Abbreviations: CCP: COVID-19 convalescent plasma; mAb: monoclonal antibody. RCT: randomized controlled trial; VOC: variant of concern.

Text word count 3485

Summary 300 words

Background: During pandemics, early outpatient treatments reduce the health system burden. Randomized controlled trials (RCTs) in COVID-19 outpatients have tested therapeutic agents, but no RCT or systematic review has been conducted comparing the efficacy of the main outpatient treatment classes to each other. We aimed in this systematic review of outpatient RCTs in COVID-19 to compare hospitalisation rate reductions with four classes of treatment: convalescent plasma, monoclonal antibodies, small molecule antivirals and repurposed drugs. Methods: We conducted a systematic review and meta-analysis of all COVID-19 outpatient RCTs that included the endpoint of progression to hospitalisation. We assembled, from multiple published and preprint databases, participant characteristics, hospitalisations, resolution of symptoms and mortality from January 2020 to May 21, 2023. The risk of bias from COVID-NMA was incorporated into the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. We measured heterogeneity with I². Meta-analysis by a random or fixed effect model dependent on significant heterogeneity (I² >50%) was performed. The protocol was registered in PROSPERO, CRD42022369181.

Findings: The search identified 281 studies of which 54 RCTs for 30 diverse interventions were included in the final analysis. These trials, performed largely in unvaccinated cohorts during pre-Omicron waves, focused on populations with at least one COVID-19 hospitalisation risk factor. Grouping by class, monoclonal antibodies (OR=0.31 [95% CI=0.24-0.40]) had highest efficacy, followed by COVID-19 convalescent plasma (CCP) (OR=0.69 [95% CI=0.53 to 0.90]) and small molecule antivirals (OR=0.78 [95% CI=0.48-1.33]) for hospital reduction. Repurposed drugs (OR=0.82 [95% CI- 0.72-0.93]) had lower efficacy.

Interpretation: Inasmuch as omicron sublineages (XBB and BQ.1.1) are now resistant to monoclonal antibodies, oral antivirals are the preferred treatment in outpatients where available, but intravenous interventions from convalescent plasma to remdesivir are also effective and necessary in constrained medical resource settings or for acute and chronic COVID-19 in the immunocompromised.

Funding: US Department of Defense and National Institute of Health

Research in context

Evidence before this study

We systematically searched the published and preprint data bases for outpatient randomized clinical trials of treatment of COVID-19 disease with hospitalisation as an endpoint. Previous systematic reviews and meta-analyses have confined the reviews to specific classes such as convalescent plasma, monoclonal antibodies, small molecule antivirals or repurposed drugs. Few comparisons have been made between these therapeutic classes. The trials took place both in the pre-vaccination and the vaccination era, spanning periods with dominance of different COVID variants. We sought to compare efficacy between the four classes of treatments listed above when used in outpatient COVID-19 patients as shown in randomized, placebo-controlled trials.

Added value of this study

This systematic review and meta-analysis brings together trials that assessed hospitalisation rates in diverse COVID-19 outpatient populations varying in age and comorbidities, permitting us to assess the efficacy of interventions both within and across therapeutic classes. While heterogeneity exists within and between these intervention classes, the meta-analysis can be placed in context of trial diverse populations over variant time periods of the pandemic. At present most of the world population has either had COVID-19 or been vaccinated with a high seropositivity rate, indicating that future placebo-controlled trials will be limited because of the sample sizes required to document hospitalisation outcomes.

Implications of all the available evidence

Numerous diverse therapeutic tools need to be ready for a resilient response to changing SARS-CoV-2 variants in both immunocompetent and immunocompromised COVID-19 outpatient populations. To date few head-to-head randomized controlled trials (RCTs) has compared treatment options for COVID-19 outpatients, making comparisons and treatment choices difficult. This systematic review compares outcomes among RCTs of outpatient therapy for COVID-19, taking into account time between onset of symptoms and treatment administration. We found that small-chemical antivirals, convalescent plasma and monoclonal antibodies had comparable efficacy between classes and amongst interventions within the four classes. Monoclonals have lost efficacy with viral mutation, and chemical antivirals have contraindications and adverse events, while intravenous interventions like convalescent plasma or remdesivir remain resilient options for the immunocompromised, and, in the case of CCP, in resource constrained settings with limited availability of oral drugs.

INTRODUCTION

By May 17, 2023 the world had recorded over 766 million cases and more than 6.9 million deaths from COVID-19. In the US, some 100 million cases have been recorded, with over a million deaths, while six million hospital admissions for COVID took place between August 2020 and December 2022. A pronounced spike in hospitalisations for COVID-19 in the US took place in the first two months of 2022 with the arrival of the Omicron variant of concern (VOC). Several approaches to reducing the risk of hospitalisation have been taken during the pandemic, including administering COVID-19 convalescent plasma (CCP), monoclonal antibodies (mAbs), small molecule antivirals or repurposed drugs. Vaccination and boosters have substantially reduced the hospitalisation and death risk, but outpatients at elevated severe COVID risk can still benefit from early treatment to avoid hospitalisation. Randomized controlled trials (RCTs) in outpatients have tested therapeutic agents against placebo or standard of care, but very few RCTs has been conducted that compare the main outpatient treatment classes. The first outpatient treatments for COVID-19 authorized by the FDA were for mAbs (bamlanivimab, bamlanivimab plus etesevimab¹ or casirivimab plus imdevimab²), approvals that preceded the introduction of mRNA vaccines^{3,4}. While many small molecules were repurposed as antivirals during the early stages of the pandemic, oral antivirals developed against SARS-CoV-2 for outpatients were not authorized and available until December 2021, when nirmatrelvir/ritonavir⁵ and molnupiravir⁶ were approved. The following month, intravenous remdesivir was also approved for outpatient use⁷. On December 2021, nearly two years after the

nirmatrelvir/ritonavir⁵ and molnupiravir⁶ were approved. The following month, intravenous remdesivir was also approved for outpatient use⁷. On December 2021, nearly two years after the first use of CCP, the FDA approved CCP outpatient use, but only for immunocompromised patients^{8,9}. The mAbs have been withdrawn due to viral variants BQ.1.* and XBB.* resistance. Here we assemble outpatient RCTs of COVID-19 different therapies, sharing either all cause or COVID-19 related hospitalisation for an endpoint. A literature search of MEDLINE (through PubMed), medRxiv and bioRxiv databases was carried out aiming to include all such RCTs published from March 2020 to October 2022 and these are summarized in the PRISMA chart (Figure 1). This systematic review and meta-analysis of outpatient COVID-19 RCTs, compared outcomes amongst CCP, mAbs, antivirals or repurposed drugs taking into account risk factors for progression, intervention dosage, time between symptom onset and treatment administration, and predominant variants of concern during RCTs.

METHODS

The protocol has been registered in PROSPERO, the prospective register of systematic reviews and meta-analyses of the University of York (protocol registration number CRD42022369181). We assembled outpatient COVID-19 RCTs with hospitalisation or a single CCP study with life-threatening respiratory distress¹⁰ as the outcome, by searching MEDLINE (through PubMed), medRxiv and bioRxiv databases for the period of March 1, 2020 to May 22, 2022, with English language as the only restriction. The Medical Subject Heading (MeSH) and search query used were: "("COVID-19" OR "SARS-CoV-2" OR "coronavirus disease 2019") AND ("treatment" OR "therapy") AND ("outpatient") AND ("hospitalisation")" AND ("randomized clinical trial"). We also screened the reference list of reviewed articles for studies not captured in our initial search. We excluded case reports, case series, retrospective, propensity-matched studies, non-randomized clinical trials, review articles, meta-analyses, studies with fewer than 30 participants, studies that did not record or had no hospitalisations. and articles reporting only aggregate data. Trials of COVID prevention¹¹ were excluded, even if hospitalisations were recorded. Articles underwent a blind evaluation for inclusion by two assessors (D.S. and D.F.) and disagreements

were resolved by a third senior assessor (A.C.). Figure 1 shows a PRISMA flowchart of the literature reviewing process. The following parameters were extracted from studies: baseline SARS-CoV-2 serology status, time from onset of symptoms to treatment, study dates, recruiting countries, gender, age (including the fraction of participants over age 50, 60 and 65), ethnicity, risk factors for COVID-19 progression (systemic arterial hypertension, diabetes mellitus, and obesity), sample size, dosage type of control, hospitalisations and deaths in each arm, and time to symptom resolution. Study dates were used to infer predominant VOCs.

Assessment of risk of bias and GRADE assessment

A risk of bias assessment of each selected RCT was performed by COVID-19-NMA initiative 12,13 . Within-trial risk of bias was assessed, using the Cochrane ROB tool for RCTs 14 . We explored clinical heterogeneity (e.g., risk factors for progression, time between onset of symptoms and treatment administration, and predominant variants of concern at the time of the interventions) and calculated statistical heterogeneity using τ^2 , Cochran's Q and estimated this using the I² statistic, which examines the total variation percentage across studies due to heterogeneity rather than chance.

We used the GRADE (The Grading of Recommendations Assessment, Development and Evaluation) system criteria to assess the quality of the body of evidence associated with specific outcomes, and constructed a 'Summary of Findings' table (Appendix Table 3), which defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest¹⁴. Publication bias was assessed by visual inspection of funnel plots.

Statistical methods

Descriptive analysis included time-to-treatment, geography (country) of the study, age, sex, race, ethnicity, seropositive, hospital type and medical high-risk conditions. The unweighted pooling ARR, RRR, NNT were calculated based on the arithmetic summation of the total hospitalisation or death numbers in each therapeutic category.

Odds ratios (OR) and 95% confidence intervals (CI) were used to show the direction of effect and its significance in comparing treatment group and control groups. The studies were weighted with the Mantel-Haenszel method. The effect heterogeneity was calculated estimating the I-squared (I^2) inconsistency index. If significant heterogeneity was detected ($I^2 > 50\%$ and Cochran's Q test for heterogeneity was significant (p < 0.10)), a random effect model was performed; otherwise, a fixed (common) effect model was performed. Weight, heterogeneity, between-study variance, and significance level were displayed in forest plots.

The significance level was 0.05. The figures were created in Prism software, R (version 4.2.1) and its statistical package "meta" (version 6.0-0). All the data manipulation and the analyses were performed in Excel, Prism, MedCalc (version 20.106), R and REVMAN.5. Role of the funding source

The study sponsors did not contribute to the study design; to the collection, analysis, and interpretation of data; to manuscript preparation, nor to the decision to submit the paper for publication.

RESULTS

TRIAL CHARACTERISTICS

We reviewed in detail 54 distinct outpatient RCTs (30 different interventions), conducted from March 2020 to May 22, 2023, across waves sustained by different SARS-CoV-2 variants of concern (VOC) and different vaccination periods in diverse patient populations (Figure 2). The studies varied in reporting outcomes of hospitalisation, whether all-cause or COVID-19 related. The CCP group included 3 RCTs with all-cause hospitalisation, 2 trials with COVID-19 related hospitalisations only and one trial with life-threatening respiratory distress in elderly individuals, deemed equivalent to hospital outcome (Appendix Table 1). The mAb RCTs included 3 trials with all-cause hospitalisations and 5 that used COVID-19 related hospitalisations as the outcome. The small molecule antivirals had 6 RCTs with all-cause hospitalisations and 5 with COVID-19 related hospitalisations, while 17 RCT's of repurposed drugs used all-cause hospitalisations and 10 trials restricted to COVID-19 related hospitalisations. Here we report the hospitalisations as a composite of the hospital types. Because inclusion criteria varied across the RCTs, the power to detect a difference in hospitalisation rates varied across studies. Three CCP RCTs had higher control arm hospitalisation rates (11% - 31%) than all other antiviral RCTs, indicating that they studied sicker populations. (Table 1 and Figure 3). The six mAb RCTs had hospitalisation rates in the controls of 4.6-8.9%, the same range as CSSC-004⁹ (6.3%). Control hospitalisation rates in the molnupiravir-MOVE-OUT⁷, nirmatrelvir/ritonavir⁵ and remdesivir¹⁵ RCTs ranged from 5.3% to 9.7%. Low hospitalisation rates were found in RCTs that had many vaccinees (metformin-COVID-OUT $-3.2\%^{16}$) or in which most participants were seropositive (molnupiravir-PANORAMIC -0.8%). Low control arm hospitalisation rates were also found in two mAb RCTs – the bebtelovimab trial $(1.6\%)^{17}$ and REGN-CoV phase 1/2 (<2%), with the bebtelovimab RCT focusing on low-risk patients ¹⁷

TRIAL FINDINGS

Examining RCTs by agent class, statistically significant relative risk reductions in hospitalisation were found in two of five CCP RCTs, six of nine mAb RCTs, four of 17 small molecule antiviral RCTs, but just 2 of 39 repurposed drug RCTs (Appendix Table 2). Except for the bebtelovimab RCT (2 hospitalisations in each arm¹⁷), mAb RCTs reduced the risk of hospitalisation by 50-80% (average 75%). Two of the three small molecule antiviral drugs (remdesivir¹⁵ and nirmatrelvir/ritonavir⁵) showed very high levels of relative risk reduction - 87% and 88% respectively - but molnupiravir reduced risk of hospitalisation by only 30%⁷ (no reduction in the PANORAMIC RCT²⁵). The lopinavir/ritonavir combination was associated with a non-significant increase in risk of hospitalisation¹⁸.

Among repurposed drug RCTs, all except metformin (58%) and sulodexide (40%), showed small and non-significant relative risk reductions of hospitalisation - ivermectin¹⁹, colchicine²⁰, fluvoxamine²¹ and hydroxychloroquine¹⁸. The nitazoxanide²² RCT found one hospitalisation among 184 treated participants compared to five hospitalisations among 195 controls, too few events to achieve significance.

Absolute risk reductions (ARR) and number needed to treat (NNT) to avert hospitalisations varied across studies and treatment classes (Appendix Table 2). In general, except for the repurposed drugs the absolute risk difference approximated 3% if one excludes the molnupiravir-Panoramic Study from SMA. The CCP RCTs had an ARR of 3.2% (95%CI-0.9-5.6), mAbs RCTs had an ARR of 4.0% (95%CI-3.2-4.8), small molecule antivirals excluding molnupiravir-Panoramic had ARR of 2.1% (95%CI-1.3-2.9) and the repurposed drugs had a smaller ARR at

1.1% (95%CI-0.5-1.6). The number needed to treat to prevent hospitalisations approximated 30 in the trials, with a few notably low with CCP-Argentina (NNT=7) Nirmatrelvir/ritonavir (NNT=18), except those using repurposed drugs, where NNT averaged 70 (Appendix Table 2). In the pooled meta-analysis by class group, the CCP RCTs had a fixed effect OR of 0.69 (95% CI=0.53 to 0.9) with moderate heterogeneity (I²=43%), the mAbs had a fixed effect OR of 0.31 (95% CI=0.24-0.40) with low heterogeneity (I²=0%), the small molecule antivirals had a random effect OR of 0.78 (95% CI=0.48-1.33) with high heterogeneity (I²=69%) and the repurposed drugs had a random effect OR of 0.82 (95% CI- 0.72-0.93) with low heterogeneity (I²=0) (Figure 4, Appendix Table 2). A biologic reason to use a fixed model for CCP and mAbs is that both formulations have the same active agent as specific antibody and thus there is a high degree of similarity in these two antibody interventions. Both antiviral small molecules and repurposed drugs comparison involve many types and classes of drugs for which the random effect model for the group is biologically more plausible than treating them as fixed. The meta-analysis of all interventions had a random effect OR of 0.67 (95% CI=0.57-0.80) with high heterogeneity (I²=52%) (Appendix Figure 2). Within the CCP RCTs excluding either CCP-Argentina for the nonhospital endpoint or CONV-ERT for methylene blue inactivation of antibody function only changed the OR by 0.05 with 95% CI remaining less than 1 for the fixed effect model (Appendix Figure 3A,B). Adding the 7 all-cause hospitalisations to CSSC-004, increased the OR by 0.02 and 95% CI by 0.01, essentially no change (Appendix Figure 3C).

Ten RCTs compared hospitalisation rates in early or late interventions (dated from symptom onset) that were extractable from the published papers or supplementary data as a post-hoc analysis (Figure 5). The small molecule drugs showed no significant reduction in the OR with segregation of early treatment from late treatment. In contrast, the antibody therapies showed a difference by treatment timing. Pooling the two classes of antibody treatment, the OR for early treatment was 0.65 (95%CI=0.49-0.85), while the OR for later treatment was 0.86 (95%CI=0.66-1.12).

All four trial classes showed reduced rates of hospitalisation for each group. The final certainty of the available evidence with GRADE assessment (Appendix Table 4) showed a high certainty level within CCP trials, moderate certainty with mAbs, and low certainty with small molecule antivirals and repurposed drugs. The main reason for downgrading individual and pooled studies was imprecision, related to small number of participants and the wide confidence intervals around the effect, followed by ROB (Appendix Figure 4). We did not find concerns in any of the GRADE factors for CCP RCTs so we graded them as high level of certainty. mAbs were downgraded to moderate certainty due to ROB (in 4 of the 8 included RCTs, ROB for the outcome hospitalisation was judged of some concern). In the cumulative analysis, small molecule antivirals were downgraded to low certainty of evidence because of ROB (some/high ROB in 4 RCTs) and inconsistency (due to high heterogeneity), while repurposed drugs were downgraded to low certainty due to ROB (some/high ROB in 5 of the 11 comparisons) and indirectness (due to large difference in mechanism of action of the included drugs). The ROB was independently evaluated by the COVID-19-Network Meta-Analysis (NMA) initiative for most of the RCTs (Appendix Figure 4 and full output ROB in Supplementary Information). Funnel plot analysis shows a low risk of publication bias except for the mAbs, for which either the efficacy of high dose antibodies or non-reporting bias are plausible explanations (Appendix Figure 5).

While several RCTs showed fewer deaths in the treatment arm, no outpatient study was powered to compare differences in mortality. Because of the low rate of deaths during trials the absolute

risk reductions amongst the 4 antiviral classes are all below 1% corresponding to relative risk reductions of 20%, 81%, 87% and 22% for CCP, mAbs, small molecule antivirals or repurposed drugs, respectively (Appendix Table 4).

TIME TO RESOLUTION

The two most effective CCP RCTs (Argentine¹⁰ and CSSC-004⁹) did not compare time to symptom resolution, while the COV-Early²³ and ConV-ert²⁴ RCTs reported no difference in the median time of symptom resolution in the two groups²⁴ (Appendix Table 2). The mAbs noted faster resolution by 1, 2, 3, 4 or 5 days for bamlanivimab/etesevimab²⁵, bebtelovimab¹⁷, regdanvimab²⁶, casirivimab/imdevimab², or redanvimab²⁷ respectively. The smaller bamlanivimab-only RCT did not show a difference¹. Of the three SMAs that noted reductions in hospitalisations, molnupiravir was associated with no difference in time of symptom resolution in MOVe-OUT⁷ but improvements in both PANORAMIC²⁵ and Aurobindo²⁷ RCTs. The 3-day outpatient remdesivir RCT showed that symptoms were alleviated by day 14 nearly twice as often¹⁵. The nirmatrelvir/ritonavir RCT did not report on this parameter⁵. Seven of 10 RCTs in the antiviral group did not show faster symptom resolution with intervention. The three RCTs largely performed in Brazil for fluvoxamine, ivermectin¹⁹ and hydroxychloroquine¹⁸ noted no differences in symptom resolution. Metformin did not evidence faster symptom resolution despite reducing hospitalisations. Three of the 25 RCTs reporting symptom resolution in the repurposed drug group noted faster symptom resolution.

COSTS

mAbs and intravenous remdesivir schedules cost about 1000 to 2000 Euros per patient, respectively, while the oral drugs are much less than 1000 Euros per patient (Table 1). By comparison, the cost of CCP approximates 200 Euros per patient, and the cost for repurposed drugs is even lower. Considering the absolute risk reduction in hospitalisation, the number needed to treat to prevent a single hospitalisation is often very high, as are the associated costs. With the recently patented antivirals, costs for outpatient treatment often exceed the cost of a COVID-19 hospitalisation²⁸.

mAbs successively lost efficacy against Delta and Omicron, with cilgavimab (the only Omicronactive ingredient in EvusheldTM) and bebtelovimab also failing against BQ.1.1 and XBB.* sublineages (Figure 6). This has led the FDA to withdraw EUAs, while EMA has not restricted usage at all. Small molecule antivirals retain *in vitro* efficacy against Omicron, but concerns remain: molnupiravir showed low efficacy *in vivo*⁶ and is mutagenic for mammals *in vitro*²⁹, while nirmatrelvir/ritonavir has drug/drug interaction contraindications (CYP3 metabolites especially tacrolimus, anti-cholesterol, anti-migraine or many anti-depressants) and has been associated with early virological and clinical rebounds in immunocompetent patients³⁰. CCP from unvaccinated donors does not inhibit Omicron, but CCP from donors having any sequence of vaccination and recent, within 6 months, COVID-19 or having had boosted mRNA vaccine doses universally has high Omicron-neutralizing activity.

DISCUSSION

The pharmaceutical industry – with well-established internal resources for trials and substantial economic support – was able to perform large outpatient trials of mAbs early in the pandemic. Inpatient services are generally more accessible to physician-scientists working in academic medical centers. The relative ease of conducting inpatient RCTs may have led most initial CCP,

small molecule antiviral and repurposed trials – which were conducted principally by academic institutions - to be based in hospitals, often in patients treated too late for antiviral treatment to be expected to work, given that antiviral therapy must be given early in disease. The constrained resources available for clinical research by academic medicine during pandemic conditions further interfered with trial work, and several potentially valuable RCT's with promising findings were terminated before they could provide definitive data. The findings of such trials are reported as null but often viewed as negative, notwithstanding trends towards effectiveness, and are rarely incorporated into clinical recommendations.

Consistent with the above, outpatient RCT data confirm that most antiviral/antimicrobial therapies are more effective when given before hospital admission. In examining the full assembly of these effective, yet molecularly disparate interventions, we note the consistent importance of early outpatient treatment for patients at risk of progression to hospitalisation³¹. Treatment within 5 days of illness onset was more effective than later treatment, as would be expected for an antiviral mechanism of action. An individual participant meta-analysis of CCP that investigated the effects of early compared to late treatment and of high compared to low dose antibody levels found that both early treatment and high levels of antibody combined to most effectively reduce risk of hospitalisations³².

The paucity of head-to-head RCT comparisons amongst outpatient COVID-19 therapies, however, makes the choice of therapy difficult. The outpatient RCTs reviewed here were conducted during different time-periods during the pandemic, thus targeting different variants, and enrolled participants with different vaccination statuses. Further heterogeneity was contributed by variation across the 54 RCTs, in participant age, medical risk factors and serological status These limitations need to be considered in our head-to-head meta-analysis of COVID-19 outpatient placebo controlled RCTs.

The choice, however, has been narrowed in recent months, and the clinical armamentarium has been reduced to small molecule antivirals, repurposed drugs and CCP, because single and double ("cocktail") MAbs have lost effectiveness against new VOCs³³. Both vaccine-elicited and disease-elicited antibodies are polyclonal, meaning that they include various isotypes that provide functional diversity and target numerous epitopes making variant escape much more difficult with CCP. Hence, polyclonal antibody preparations are much more resilient to the relentless evolution of variants. This is in marked contrast to mAbs, which target single epitopes of SARS-CoV-2. The exquisite mAb (and receptor binding domain) specificity renders mAbs susceptible to becoming ineffective with single amino acid changes. Plasma from individuals who have been both vaccinated and boosted is characterized by high amounts of neutralizing antibodies which can be effective against practically any existing VOC, including Omicron³⁴ (so-called "heterologous immunity", likely due to the well-known phenomenon of "epitope spreading"). Vaccine-boosted CCP has more than ten times the amount of total SARS-CoV-2 specific antibody and viral neutralizing activity compared to the pre-omicron CCP used in the effective outpatient CCP RCTs.

In addition to efficacy, other points to consider in an outpatient pandemic are tolerability, scalability and affordability. Repurposed drugs are generally well tolerated, widely available and relatively inexpensive, but, as we have shown, have limited efficacy. By contrast, small molecule antivirals are often plagued by contraindications and side effects, which make several classes of patients reliant on passive immunotherapies. Both small molecule antivirals and mAbs take time to develop and are unaffordable in low-and-middle income countries (LMIC). CCP is instead a

tolerable, scalable, and affordable treatment and is usually provided in a single IV session, in contrast to Remdesivir, which requires a three-day intravenous course.

On Dec. 28, 2021 the FDA expanded the authorized emergency use of convalescent plasma with high titers of anti-SARS-CoV-2 antibodies "for the treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment, in either the outpatient or inpatient setting." This EUA noted that CCP was safe and effective in immunocompetent individuals and allowed under the emergency measure of the pandemic, but expanded its use in immunosuppressed individuals to outpatient use, notwithstanding the availability of oral drugs and (at that time) two remaining effective mAb treatments for the new omicron variants of concerns

The published mAbs RCTs assembled here showed better efficacy than other outpatient interventions, yet are now clinically ineffective against BQ.1.* and XBB.* Omicron variants. CCP and small molecule antivirals have comparable levels of effectiveness, but the latter have many contraindications and side effects. Repurposed drugs are either ineffective or mildly effective. That leaves CCP, which is especially important in the immunosuppressed but, as the trials show, early treatment with high levels of antibody, has value in other populations as well. Our clinical recommendation from this review is to use CCP on an out-patient basis in regions with no other therapy available regardless of vaccination status for those at high risk of progression to hospitalisation.

FUNDING

This study was supported by the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (DS, AC, DH), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1 (DS, AC), NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098 (DH).

CONTRIBUTORS

DS wrote the first draft and extracted data verified by DF, and MF. DF curated Table 3 and 7 and revised the text. MC, JO, MF and DS performed statistical analyses. MC and DS performed GRADE assessment. AC, NP, MF and DH critically revised the manuscript. DS and DF directly accessed and verified the underlying data reported here. All authors read and agree with manuscript.

DECLARATION OF INTERESTS

DS, DFH, AC were investigators in the CSSC-004 study; D.F. and M.F. were investigators in the TSUNAMI RCT of CCP. DJS reports AliquantumRx Founder and Board member with stock options (macrolide for malaria), Hemex Health malaria diagnostics consulting and royalties for malaria diagnostic test control standards to Alere- all outside of submitted work. AC reports being part of the scientific advisory board of SabTherapeutics and has received personal fees from Ortho Diagnostics, outside of the submitted work. All other authors report no relevant disclosures.

DATA SHARING

Datasets used for this systematic review are publicly available in PubMed, medRxiv and bioRxiv.

REFERENCES

- 1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med* 2021; **384**(3): 229-37.
- 2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med* 2021; **385**(23): e81.
- 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
- 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med* 2020; **383**(25): 2427-38.
- 5. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med* 2022; **386**(15): 1397-408.
- 6. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2022; **386**(6): 509-20.
- 7. FDA. FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19. In: FDA, editor.; 2022.
- 8. O'Shaughnessy JA. Convalescent Plasma EUA Letter of Authorization 12282021
- . FDA website (https://www.fda.gov/media/141477/download); 2021.
- 9. Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med* 2022.
- 10. Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021; **384**(7): 610-8.
- 11. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. *New England Journal of Medicine* 2021; **385**(13): 1184-95.
- 12. Nguyen TV, Ferrand G, Cohen-Boulakia S, et al. RCT studies on preventive measures and treatments for COVID-19. *Zenodo* 2020.
- 13. Boutron I, Chaimani A, Meerpohl JJ, et al. The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. *Ann Intern Med* 2020; **173**(12): 1015-7.
- 14. JPT H, S G, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: www.handbook.cochrane.org; 2011.
- 15. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med* 2022; **386**(4): 305-15.
- 16. Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. *N Engl J Med* 2022; **387**(7): 599-610.
- 17. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. *medRxiv* 2022: 2022.03.10.22272100.
- 18. Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**(4): e216468.
- 19. Reis G, Silva E, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. *N Engl J Med* 2022.

- 20. Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respir Med* 2021; **9**(8): 924-32.
- 21. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health* 2022; **10**(1): e42-e51.
- 22. Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Brechot C. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. *EClinicalMedicine* 2022; **45**: 101310.
- 23. Millat-Martinez P, Gharbharan A, Alemany A, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. *Nature Communications* 2022; **13**(1): 2583.
- 24. Alemany A, Millat-Martinez P, Corbacho-Monne M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. *Lancet Respir Med* 2022; **10**(3): 278-88.
- 25. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med* 2021; **385**(15): 1382-92.
- 26. Streinu-Cercel A, Sandulescu O, Preotescu LL, et al. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* 2022; 9(4): ofac053.
- 27. Kim JY, Sandulescu O, Preotescu LL, et al. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* 2022; **9**(8): ofac406.
- 28. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA* 2021; **326**(6): 490-8.
- 29. Zhou S, Hill CS, Sarkar S, et al. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *J Infect Dis* 2021; **224**(3): 415-9.
- 30. Gupta K, Strymish J, Stack G, Charness M. Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. *Research Square* 2022.
- 31. Hasan Ali O, Bomze D, Risch L, et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. *Clinical Infectious Diseases* 2020.
- 32. Levine AC, Fukuta Y, Huaman MA, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. *Clin Infect Dis* 2023.
- 33. Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. *International Journal of Molecular Sciences* 2023; **24**(3): 2264.
- 34. Focosi D, Franchini M, Joyner MJ, Casadevall A. Comparative analysis of antibody responses from COVID-19 convalescents receiving various vaccines reveals consistent high neutralizing activity for SARS-CoV-2 variant of concern Omicron. 2021: 2021.12.24.21268317.
- 35. Gharbharan A, Jordans C, Zwaginga L, et al. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial. *Clin Microbiol Infect* 2022.

- 36. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. *N Engl J Med* 2021; **385**(21): 1951-60.
- 37. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med* 2021.
- 38. Norton T, Ali S, Sivapalasingam S, et al. REGEN-COV Antibody Combination in Outpatients With COVID-19 Phase 1/2 Results. *medRxiv* 2022: 2021.06.09.21257915.
- 39. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* 2022; **10**(10): 985-96.
- 40. Butler C, Hobbs FDR, Gbinigie O, et al. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial. *SSRN* 2022; **ssrn.4237902**.
- 41. Tippabhotla SK, Lahiri S, Rama Raju D, Kandi C, Prasad VN. Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial. . SSRN 2022; 4042673.
- 42. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. *N Engl J Med* 2023; **388**(6): 518-28.
- 43. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021; **9**(5): 498-510.
- 44. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nature Communications* 2021; **12**(1): 1967.
- 45. Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *Journal of Antimicrobial Chemotherapy* 2020; **76**(3): 753-7.
- 46. Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. *Clin Microbiol Infect* 2022; **28**(4): 602-8.
- 47. Vaezi A, Salmasi M, Soltaninejad F, Salahi M, Javanmard SH, Amra B. Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. *Adv Respir Med* 2023; **91**(1): 18-25.
- 48. Lowe DM, Brown LK, Chowdhury K, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. *PLoS Med* 2022; **19**(10): e1004120.
- 49. Kaizer AM, Shapiro NI, Wild J, et al. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. *Int J Infect Dis* 2023; **128**: 223-9.
- 50. Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. *EClinicalMedicine* 2021; **38**: 100993.
- 51. Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. *Lancet Reg Health Am* 2022; **6**: 100142.

- 52. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* 2020; **324**(22): 2292-300.
- 53. McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2023; **329**(4): 296-305.
- 54. Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial. *Ann Intern Med* 2023; **176**(5): 667-75.
- 55. Reis G, Silva E, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. *N Engl J Med* 2022; **386**(18): 1721-31.
- 56. Rezai MS, Ahangarkani F, Hill A, et al. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. *Front Med (Lausanne)* 2022; **9**: 919708.
- 57. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2022; **328**(16): 1595-603.
- 58. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. *JAMA* 2023; **329**(11): 888-97.
- 59. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. *Ann Intern Med* 2020; **173**(8): 623-31.
- 60. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *CMAJ Open* 2021; **9**(2): E693-E702.
- 61. Mitja O, Reis G, Boulware DR, et al. Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. *Clin Transl Sci* 2023; **16**(3): 524-35.
- 62. Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *EClinicalMedicine* 2021; **33**: 100773.
- 63. Spivak AM, Barney BJ, Greene T, et al. A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. *Microbiol Spectr* 2023; **11**(2): e0467422.
- 64. Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. *Int J Antimicrob Agents* 2021; **58**(5): 106428.
- 65. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *EClinicalMedicine* 2021; **37**: 100957.
- 66. Cairns DM, Dulko D, Griffiths JK, et al. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial. *JAMA Network Open* 2022; **5**(2): e2144942-e.

- 67. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. *JAMA* 2021; **326**(17): 1703-12.
- 68. Gonzalez-Ochoa AJ, Raffetto JD, Hernandez AG, et al. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. *Thromb Haemost* 2021; **121**(7): 944-54.
- 69. Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol* 2022; **9**(8): e594-e604.
- 70. Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol* 2022; **9**(8): e585-e93.
- 71. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA Intern Med* 2022; **182**(1): 42-9.
- 72. Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). *Clin Microbiol Infect* 2022; **28**(7): 1010-6.
- 73. Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**(2): e210369.
- 74. Adler UC, Adler MS, Padula AEM, et al. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). *J Integr Med* 2022; **20**(3): 221-9.
- 75. Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, et al. Efficacy of a multiple-indication antiviral herbal drug (Saliravira(R)) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. *Biomed Pharmacother* 2022; **149**: 112729.
- 76. Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. *Lancet Respir Med* 2021; **9**(10): 1130-40.
- 77. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). *Sci Rep* 2022; **12**(1): 10978.

Figure 1 PRISMA flowchart for randomized controlled trials (RCT) selection in this systematic review.




Figure 2 Duration and calendar months of the RCT in context of dominant variant(s) of concern and seropositivity rates. Study start and end for enrollments are charted with approximate time periods for variants of concern.

																																, ,
																																Baseline
			MAR-										IAN-												IAN-							Antibody Positive
TYPE	Study	months	20	APR	MAY	IIIN	JUL	AUG	SEP	ост	NOV	DEC	JAIN- 21	FEB	MAR	ΔPR	MAY	IIIN	11 11	AUG	SEP	ОСТ	NOV	DEC		FFR	MΔR	APR	ΜΔΥ	ILIN		%
Ab-CCP	CCP-CONV-ert	9	20	Arix	IVIAI	3014	JUL	AUG	JLI	OCI	1	2	3	4	5	6	7	8	9	700	JEI	oci	1404	DEC	22	TEB	IVIAIN	Arix	IVIAI	3014	JOL	11%
Ab-CCP	CCP-COV-early	10								1	2	3	4	5	6	7	8	9	10												T	8%
	CCP-C3PO	7						1	2	3	4	5	6	7																		NR
	CCP-Argentina	5				1	2	3	4	5																						NR
Ab-CCP	CCP-CSSC-004	16				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16										<u> </u>	NR
	Bamlanivimab-BLAZE-1	3							1	2	3																				<u> </u>	NR
	Sotrovimab-COMET-ICE	6							1	2	3	4	5	6																	₩	NR NR
mAb	Bamlanivimab/etesevimab-BLAZE-1 Casirivimab/imdevimab-REGEN-COV Ph 3	3							1	2	3	2	4																		₩-	23%
mAb	Casirivimab/imdevimab-REGEN-COV Ph 1/2	2					1	2	2	1		3	-																		-	38%
mAb	Bebtelovimab-BLAZE-4	3					-	-	,								1	2	3												†	11%
	Regdanvimab-CT-P59	2								1	2																					3%
mAb	Regdanvimab-CT-P59-2	3												1	2	3																11%
mAb	Tixagevimab-cilgavimab-TACKLE	6												1	2	3	4	5	6													14%
SMA	Molnupiravir-MOVe-OUT	6															1	2	3	4	5	6									<u> </u>	23%
	Molnupiravir-PANORAMIC	5										1	2	3	4	5															₩	98%
SMA	Molnupiravir-Aurobindo	2			-		-	-	-	\vdash			1	-	-	-	-		1	2	2		-					-			₩	NR
SMA SMA	Nirmatrelvir/ritonavir-EPIC-HR Remdesivir-PINETREE	6 8					 		1	2	3	4	5	6	7.	8			1	2	- 3	4	3	6							\vdash	11% 3%
	Interferon Lambda-TOGETHER	8							1		,	•	,	0	,	٥			1	2	3	4	5	6	7	8					H	NR
SMA	Interferon Lambda-ILIAD	4			1	2	3	4					1	t																	T	10%
	Interferon Lambda-COVID-Lambda	2			1	2			1					İ																		41%
SMA	Sofosbuvir & daclatasvir-SOVODAK	1		1																												NR
	Favipiravir-Avi-Mild-19	12						1	2	3	4	5	6	7	8	9	10	11	12												ш	NR
SMA	Favipiravir-Iran	4									_	1	2	3	4	_				4.	4.7										₽	NR
SMA	Favipiravir-FLARE Favipiravir/Lopinavir/Ritonavir-FLARE	13 13			-					1	2	3	4	5	6	7	8	9	10	11	12	13									₩	62% 64%
SMA	Lopinavir/Ritonavir-FLARE	13								1	2	3	4	5	6	7	8	9	10	11	12	13									₩	62%
SMA	Lopinavir/ritonavir-TREAT NOW	18				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18								†	21%
SMA	Lopinavir/ritonavir-TOGETHER	4				1	2	3	4																							NR
	Tenofovir/Emtricitabine-AR0-CORONA	4										1	2	3	4																	NR
	Metformin-COVID-OUT	13											1	2	3	4	5	6	7	8	9	10	11	12	13						<u> </u>	52% FV
	Metformin -TOGETHER	3											1	2	3																₩	NR
RP RP	Fluvoxamine-TOGETHER	8				0							1	2	3	4	5	6	7	8											₩.	NR NR
	Fluvoxamine -STOP COVID	4		1	2	3	4							2	2		-	-	7	0	0	10	44	12	12						₩-	
RP	Fluvoxamine-COVID-OUT Fluvoxamine-ACTIV-6	13 10											1	2	3	4	5	6	/	8	9	10	11	12	13	7	8	q	10		-	56% FV 67%
RP	Fluvoxamine/budesonide-TOGETHER	6																		-	-	,	_		1	2	3	4	5	6		94%
RP	Ivermectin-TOGETHER	5														1	2	3	4	5												NR
RP	Ivermectin-COVID-OUT	13											1	2	3	4	5	6	7	8	9	10	11	12	13							56% FV
	Ivermectin Iran	7												1	2	3	4	5	6	7											<u> </u>	NR
RP	Ivermectin-ACTIV-6	7																	1	2	3	4	5	6	7							47%
RP	Ivermectin high dose-ACTIV-6	5											-														1	2	3	4	5	84% FV
RP RP	Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP	4	1	2		1	2	3	4				-																		₩	NR NR
	Hydroxychloroquine -AH COVID-19	1	1	2	1																										-	NR
	Hydroxychloroquine-BCN PEP-CoV-2	2		1	2																										†	NR
RP	Hydroxychloroquine-BMG	3		1	2	3																										NR
RP	Hydroxychloroquine-Utah	12		1	2	3	4	5	6	7	8	9	10	11	12																	NR
RP	Hydroxychloroquine/Azithromycin-Brazil	1			1		\perp							L	\perp	L												L			ᅜ	NR
RP	Nitazoxanide-Romark	5			_			1	2	3	4	5		1	1	1	-			\vdash								1			₩	10%
RP RP	Colchicine-COLCORONA Losartan-MN	9	1	2	3	4	5	5	7	8	9		1	-	-	-	-			\vdash								-			₩	NR NR
	Niclosamide	7		1		3	**	-	0	1	2	3	4	5	6	7															\vdash	NR NR
	Aspirin-ACTIV-4B	10							1	2	3	4	5	6	7	8	9	10													H	NR NR
RP	2.5-mg apixaban-ACTIV-4B	10					<u> </u>		1	2	3	4	5	6	7	8	9	10														NR
RP	5-mg apixaban ACTIV-4B	10							1	2	3	4	5	6	7	8	9	10														NR
RP	Sulodexide	2				1	2																								ഥ	NR
RP	Enoxaparin-ETHIC	12									4	2	3	4	5	6	7	8	9	10	11	12									تــــا	NR
RP	Enoxaparin-OVID	17	\vdash		.		-	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17				1			₩	NR
RP RP	Inhaled Ciclesonide-COVIS Inhaled ciclesonide-COVERAGE	5 7				1	2	3	4	5			1	2	3	4	5	6	7	\vdash								-			₩	NR NR
	Zinc Zinc Zinc Zinc Zinc Zinc Zinc Zinc	6			1	2	3	4	5	6			1	2	5	4	5	В	/												\vdash	NR NR
RP	Ascorbic acid	6			1	2	3	4	5	6			1	t																	T	NR
RP	Zinc/Ascorbic acid	6			1	2	3	4	5	6																						NR
	Homeopathy-COVID-Simile	10					1	2	3	4	5	6	7	8	9	10	\Box											L			ᅜ	NR
RP	Saliravira	3			ļ							1	2	3	ļ																₽	NR
	Azithromycin-Atomic2	8	\vdash		—	1	2	3	4	5	6	7	8		1	1	-			\vdash								1			₩	NR
RP RP	Azithromycin-ACTION Resveratrol	9				1	2	3	4	5	6	7	8	9																	\vdash	NR NR
	614G	3	6146	6146	614G	6146	6146	6146			_	6146	614G	614G	614G	614G															+ -	INK
	Alpha												a	a	a	a	а	а										 			t	_
Variant	Beta													b	b	b	b															
Variant													L						d	d	d	d	d	d	d							
Wariant	Omicron	1	1	ı	l		ı	ı	I	1		1	1	1	1	1	1			1				0	0	0	0	0	0	0	1 0	4

Figure 3

Percent hospitalisations in control groups sorted by therapy type and descending control hospitalisation rates.





Figure 4 Odds ratio for hospitalisations with diverse therapeutic interventions, grouped according to mechanism of action (CCP, mAbs, small molecule antivirals and repurposed drugs). CCP- Fixed and random effect model




mAbs- Fixed and random effect model

	Interve	ention	C	ontrol				Weight	Weight
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	(common)	(random)
Bamlanivimab-BLAZE-1	5	309	9	143		0.24	[0.08; 0.74]	5.0%	5.2%
Sotrovimab-COMET-ICE	6	528	30	529		0.19	[0.08; 0.46]	12.1%	8.2%
Bamlanivimab/etesevimab-BLAZE-1	11	518	36	517		0.29	[0.15; 0.58]	14.4%	13.6%
Casirivimab/imdevimab-REGEN-COV Ph 3	18	1355	62	1341		0.28	[0.16; 0.47]	25.2%	22.8%
Casirivimab/imdevimab-REGEN-COV Ph 1/2	3	533	5	266		0.30	[0.07; 1.25]	2.7%	3.1%
Bebtelovimab-BLAZE-4	2	125	2	128		1.02	[0.14; 7.39]	0.8%	1.6%
Regdanvimab-CT-P59	9	203	9	104		0.49	[0.19; 1.27]	4.7%	7.0%
Regdanvimab-CT-P59-2	16	656	52	659	 	0.29	[0.16; 0.52]	20.7%	19.6%
Tixagevimab-cilgavimab-TACKLE	18	407	37	415	 =	0.47	[0.26; 0.84]	14.3%	19.0%
Common effect model	88	4634	242	4102	\langle	0.31	[0.24; 0.40]	100.0%	
Random effects model					~	0.32	[0.25; 0.41]		100.0%
Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.67$				Г		I			
Test for overall effect (common effect): $z = -9.03$		0.0	0.5 1 2 10	20					
Test for overall effect (random effects): $z = -8.82$	(p < 0.01))							

Small Molecule antivirals- Random effect model

	Interv	ention	c	ontrol				Weight	Weight
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	(common)	(random)
Molnupiravir-MOVe-OUT	48	709	68	699		0.67	[0.46; 0.99]	20.9%	11.3%
Molnupiravir-PANORAMIC	103	12516	96	12484	() -	1.07	[0.81; 1.42]	31.2%	11.6%
Molnupiravir-Aurobindo	0	610	0	610				0.0%	0.0%
Nirmatrelvir/ritonavir-EPIC-HR	8	1039	66	1046		0.12	[0.06; 0.24]	21.3%	9.8%
Remdesivir-PINETREE	2	279	15	283	←	0.13	[0.03; 0.57]	4.8%	6.3%
Interferon Lambda-TOGETHER	21	931	40	1018		0.56	[0.33; 0.96]	12.2%	10.8%
Interferon Lambda- ILIAD	1	30	1	30		- 1.00	[0.06; 16.76]	0.3%	2.8%
Interferon Lambda-COVID-Lambda	2	60	2	60		1.00	[0.14; 7.34]	0.6%	4.6%
Sofosbuvir and daclatasvir-SOVODAK	1	27	4	28		0.23	[0.02; 2.21]	1.2%	3.9%
Favipavir-Avi-Mild-19	6	112	2	119	# +	- 3.31	[0.65; 16.76]	0.6%	5.8%
Favipiravir-Iran	4	38	2	39		2.18	[0.37; 12.65]	0.6%	5.3%
Favipiravir-FLARE	1	59	0	60		→ 3.10	[0.12; 77.71]	0.2%	2.3%
Favipiravir/Lopinavir/Ritonavir-FLARE	1	61	0	60		→ 3.00	[0.12; 75.11]	0.2%	2.3%
Lopinavir/Ritonavir-FLARE	1	60	0	60		→ 3.05	[0.12; 76.39]	0.2%	2.3%
Lopinavir/ritonavir-TREAT NOW	7	220	6	226		1.21	[0.40; 3.64]	1.9%	8.0%
Lopinavir/ritonavir-TOGETHER	14	244	11	227	- •	1.20	[0.53; 2.69]	3.5%	9.5%
Tenofovir Disproxil Fumarate Plus Emtricitabine-AR0-CORONA	. 2	30	1	30	- .	→ 2.07	[0.18; 24.15]	0.3%	3.5%
Common effect model	222	17025	314	17079	•	0.70	[0.59; 0.84]	100.0%	
Random effects model							[0.45; 1.33]		100.0%
Heterogeneity: $I^2 = 69\%$, $\tau^2 = 0.6351$, $p < 0.01$,		
Test for overall effect (common effect): $z = -3.94$ ($p < 0.01$)				0.	05 0.5 1 2 10	20			
Test for overall effect (random effects): $z = -0.91$ ($p = 0.36$)									


Repurposed Drugs-Fixed effect model



Test for overall effect (random effects): z = -3.09 (p < 0.01)

Figure 5
Odds ratio for point estimates for hospitalisation in RCT subgroups treated A) within 5 days since onset of symptoms and also B) over 5 days within same trial.

A) Early treatment-Fixed and random effect model



B Late treatment-Fixed and random effect model




Figure 6

Venn diagram of mAb efficacy against Omicron sublineages. *In vitro* activity of currently approved mAbs against Omicron sublineages circulating as of October 2022. Specific Omicron Spike amino acid mutations causing baseline ≥ 4-fold-reduction in neutralization against mAbs are reported. Mutations for which the majority of studies are concordant are reported: the different fold-reductions for each mAb are identified across concordant studies as color coded numbers defining the mean median values of specific reduction in each study. Sourced from https://covdb.stanford.edu/page/susceptibility-data (accessed on January31, 2023 * L452R occurs in all BA.4/BA.5 lineages, but only in several BA.2. sublineages. ¹ R346X and K444X occur in a growing number of BA.2 and BA.4/5 sublineages as a result of convergent evolution.




Table 1
Hospital rates, risk reductions, NNT, numbers and symptom resolution

Hospital rates, risk re	ductions,	NNT, numb	pers and sy	mptom	resolutio	on		1			
Study	Control hospital izations %	hospitali zations % in intervent ion arm	ARR percent (95% CI)	RRR (95% (percent	NNT to prevent 1 hospitali zation	Hospitaliza tion (n) in control arm	total pts in control arm (n)	Hospitaliza tion (n) in interventio n arm	Total pts (n) in intervent ion arm	Symptom resolution: median duration- Intervention to control in days
CCP (5 RCT) % or totals	12	8.8	3.2 (0.9, 5.6)	26.8 41.7)	(8.1,	31	158	1315	116	1319	
anti-Spike mAbs (8 RCT) % or totals	5.9	1.9	4.0 (3.2, 4.8)	67.8 74.7)	(59.1,	25	242	4102	88	4634	
Small molecule antiviral (11 RCTs) total or average	1.8	1.3	0.5 (0.3, 0.8)	29.1 40.2)	(15.9,	187	314	17079	222	17025	
Small molecule antiviral (10 RCTs - w/o Mol-Pan.) total or average	4.7	2.6	2.1 (1.3, 2.9)	44.4 55.3)	(30.7,	48	218	4595	119	4509	
Repurposed drugs (20 RCTs) total or average	5.3	4.2	1.1 (0.5, 1.6)	20.1 28.9)	(10.1,	94	590	11121	483	11391	
All (47 RCTs) total or average	3.9	2.6	1.2 (1.0, 1.5)	31.8 37.3)	(25.9,	81	1304	33617	909	34369	
CCP-CONV-ert ²⁴	11.2	11.7	-0.5 (- 7.0, 5.9)	-4.8 40.3) 36.2	(-83.9,	-188	21	188	22	188	NO difference 12 d vs 12 d NO difference 13 d
CCP-COV-Early ³⁵	9.3	5.9	3.4 (-1.8, 8.5)	68.2)	(-27.9,	29	19	204	12	202	vs 12 d
CCP-C3PO ³⁶	22.0	20.2	1.8 (-5.3, 8.9)	8.2 34.4)	(-28.3,	55	56	254	52	257	NO difference
CCP-Argentina ¹⁰	31.3	16.3	15.0 (2.0, 28.0)	48.0 71.3)	(5.8,	7	25	80	13	80	Not reported
CCP-CSSC-0049	6.3	2.9	3.4 (1.0, 5.8)	54.3 74.0)	(19.7,	29	37	589	17	592	Not reported

		1	1			1	1	1		
CCP-Argentina			22.9 (9.3,	73.3 (17.4,						
(high titer) ¹⁰	31.3	8.3	36.5)	91.4)	4	25	80	3	36	Not reported
CCP-CSSC-004 (<=	9.7	1.9	7.7 (3.7,	79.9 (48.4,						
5 days) 9	J.1	1.7	11.7)	92.2)	13	25	259	5	257	Not reported
Bamlanivimab-			4.7 (0.5,	74.3 (24.7,						NO difference 11 d
BLAZE-1 ¹	6.3	1.6	8.9)	91.2)	21	9	143	5	309	to 11 d
Sotrovimab-			4.5 (2.4,	80.0 (52.3,						
COMET-ICE ³⁷	5.7	1.1	6.7)	91.6)	22	30	529	6	528	Not reported
Bamlanivimab/etese			4.8 (2.3,	69.5 (40.8,						YES- 8d vs 9d
vimab-BLAZE-1 ²⁵	7.0	2.1	7.4)	84.3)	21	36	517	11	518	p=0.007
Casirivimab/imdevi										
mab-REGEN-COV			3.3 (2.0,	71.3 (51.7,						YES- 10 d vs 14
Ph 3 ²	4.6	1.3	4.6)	82.9)	30	62	1341	18	1355	p=0.0001
Casirivimab/imdevi										
mab-REGEN-COV			1.3 (-0.4,	70.1 (-24.4,						
Ph 1/2 ³⁸	1.9	0.6	3.1)	92.8)	76	5	266	3	533	Not reported
Bebtelovimab-			-0.04 (-	-2.4 (-615.7,						YES- 6d to 8d
BLAZE-4 ¹⁷	1.6	1.6	3.1, 3.0)	85.4)	-2667	2	128	2	125	p=0.003
Regdanvimab-CT-			4.2 (-1.9,	48.8 (-25.2,						YES 6 d vs 9 d
P59 ²⁶	8.7	4.4	10.3)	79.0)	23	9	104	9	203	p=0.01
Regdanvimab-CT-										
P59-2 ²⁷			5.4 (3.1,	69.1 (46.4,						
	7.9	2.4	7.8)	82.2)	18	52	659	16	656	8 d to 13 d
Tixagevimab-										
cilgavimab-			4.5 (1.1,	50.4 (14.3,						
TACKLE ³⁹	8.9	4.4	7.9)	71.3)	22	37	415	18	407	Not reported
Molnupiravir-			3.0 (0.1,	30.4 (0.8,						
MOVe-OUT ⁶	9.7	6.8	5.8)	51.2)	34	68	699	48	709	NO difference
Molnupiravir-			-0.1 (-	-7.0 (-41.2,						
PANORAMIC ⁴⁰	0.8	0.8	0.3, 0.2)	18.9)	-1853	96	12484	103	12516	YES 9 d vs 15 d
Molnupiravir-										Yes 10 d vs 14 d
Aurobindo ⁴¹	0.0	0.0	NC	NC	0	0	610	0	610	p<0.001
Nirmatrelvir/ritonav			5.5 (4.0,	87.8 (74.7,						
ir-EPIC-HR ⁵	6.3	0.8	7.1)	94.1)	18	66	1046	8	1039	Not reported

Remdesivir-			4.6 (1.8,	86.5 (41.4,						YES- Alleviation of symptoms by day 14 (rate ratio, 1.92; 95%
PINETREE ¹⁵	5.3	0.7	7.4)	96.9)	22	15	283	2	279	CI, 1.26 to 2.94)
Interferon Lambda-			1.7 (0.1,	42.6 (3.4,						
TOGETHER ⁴²	3.9	2.3	3.2)	65.9)	60	40	1018	21	931	
Interferon Lambda-			0 (-9.1,	0 (-1426,		1				No difference
ILIAD ⁴³	3.3	3.3	9.1)	93.4)		<u> </u>	30	1	30	
Interferon Lambda-			0 (-6.4,	0 (-586.9,						NO difference 20 d
COVID-Lambda ⁴⁴	3.3	3.3	6.4)	85.4)		2	60	2	60	vs 20 d
Sofosbuvir and										
daclatasvir-			10.6 (-	74.1 (-117,						NO difference in 7 d
SOVODAK ⁴⁵	14.3	3.7	4.2, 25.4)	96.9)	9	4	28	1	27	symptoms
Favipavir-Avi-			-3.7 (-	-219 (-1447,						NO difference 7d vs
Mild-19 ⁴⁶	1.7	5.4	8.4, 1.1)	34.3)	-27	2	119	6	112	7d
			-5.4 (-	-105.3 (-						
Favipiravir-Iran ⁴⁷	5.1	10.5	17.4, 6.6)	955.6, 60.1)	-19	2	39	4	38	
Favipiravir-			-1.7 (-	NA						
FLARE ⁴⁸	0.0	1.7	5.0, 1.6)	1171	-59	0	60	1	59	
Favipiravir/Lopinav			-1.6 (-							
ir/Ritonavir-			4.8, 1.5)	NA						
FLARE ⁴⁸	0.0	1.6	1.0, 1.5)		-61	0	60	1	61	
Lopinavir/Ritonavir			-1.7 (-	NA						
-FLARE ⁴⁸	0.0	1.7	5.0, 1.6)		-60	0	60	1	60	
Lopinavir/ritonavir-			-0.5 (-	-19.8 (-251,						
TREAT NOW ⁴⁹	2.7	3.2	3.7, 2.6)	59.1)	-190	6	226	7	220	6 d to 6 d
Lopinavir/ritonavir-			-0.9 (-	-18.4 (-155.4,						NO difference by
TOGETHER ¹⁸	4.8	5.7	4.9, 3.1)	45.1)	-112	11	227	14	244	Cox proportional HR
Tenofovir Disproxil										
Fumarate Plus										
Emtricitabine-AR0-										
CORONA ⁵⁰			-3.3 (-	-100 (-						
	3.3	6.7	14.3, 7.7)	1989.8, 80.9)	-30	1	30	2	30	
Metformin-COVID-			1.8 (0.1,	57.5 (3.8,						
OUT ¹⁶	3.2	1.3	3.5)	81.3)	55	19	601	8	596	NO difference

	1	1				1	1	1	1	T 1
Metformin -										
TOGETHER ⁵¹			0.7 (-5.5,	5.6 (-60.8,						
	11.8	11.2	6.8)	44.6)	152	24	203	24	215	not reported
Fluvoxamine-			2.7 (-0.5,	21.1 (-4.8,						NO difference- 40%
TOGETHER ²¹	12.8	10.1	5.9)	40.6)	37	97	756	75	741	resolved by day 14
										YES (100% vs
Fluvoxamine-STOP			8.3 (1.9,							91.7% resolved on
COVID ⁵²	8.3	0.0	14.7)	1 (1, 1)	12	6	72	0	80	day 7) p=0.009
										No difference (14
Fluvoxamine-			-0.3 (-	-17.6 (-281,						symptoms on 4 pt
COVID-OUT ¹⁶	1.7	2.0	2.5, 1.9)	63.7)	-333	5	293	6	299	scale over 14 days)
Fluvoxamine			0.18 (-	54.7 (-398.3,						,
ACTIV-6 ⁵³	0.3	0.1	0.4, 0.7)	95.9)	555	2	607	1	670	12 d to 13 d
Fluvoxamine/budes				,						
onide-			0.1 (-0.9,	12.5 (-140.1,						
TOGETHER ⁵⁴	1.1	0.9	1.1)	68.1)	738	8	738	7	738	not reported
Ivermectin-			2.4 (-1.2,	16.8 (-9.9,	,,,,,		100		,,,,,	NO difference- 40%
TOGETHER ⁵⁵	14.0	11.6	5.9)	37.1)	42	95	679	79	679	resolved by day 14
TOUDITHER	1	1110	()	5,11)			0,75		073	No difference (14
Ivermectin-COVID-			0.3 (-1.3,	23.9 (-181,						symptoms on 4 pt
OUT ¹⁶	1.4	1.1	1.9)	79.4)	299	5	356	4	374	scale over 14 days
001	1.7	1.1	-2.1 (-	-42.3 (-178,	2))	3	330	1	3/4	scare over 14 days
Ivermectin Iran ⁵⁶	5.0	7.1	6.1, 1.9)	27.2)	-47	14	281	19	268	NO difference
Ivermectin-ACTIV-	3.0	7.1	-0.1 (-	-5.3 (-158,	-4/	17	201	1)	200	No difference (12d
6 ⁵⁷	1.2	1.2	1.1, 1.0)	57.0)	-1634	9	774	10	817	vs 13 d)
Ivermectin high	1.2	1.2	1.1, 1.0)	37.0)	-1054	9	//4	10	017	vs 13 d)
dose-ACTIV-6 ⁵⁸			-0.5 (-	-150.1 (-1188,						11 d vs 11 d no
dose-AC11V-650	0.2	0.0	`	` ′	200	2	604		602	
	0.3	0.8	1.4, 0.4)	51.1)	-200	2	604	5	602	difference
Hydroxychloroquin			1.1 (-2.7,	22.9 (-88.1,						NO difference by
e-TOGETHER ¹⁸	4.8	3.7	4.9)	68.4)	90	11	227	8	214	Cox proportional HR
										NO Difference in
Hydroxychloroquin			2.4 (-1.1,	50.2 (-43.1,						symptom severity
e-COVID-19 PEP ⁵⁹	4.7	2.4	5.9)	82.7)	42	10	211	5	212	score over 14 days
Hydroxychloroquin			-3.6 (-							NO difference 14 d
e -AH COVID-19 ⁶⁰	0.0	3.6	7.1, -0.1)	NA	-28	0	37	4	111	vs 12 d

	<u> </u>	1					1	1	1	
Hydroxychloroquin			11/45	160 (102						NO 1:00 10 1
e-BCN PEP-CoV-			1.1 (-4.5,	16.0 (-103,						NO difference 10 d
261	7.0	5.9	6.7)	65.2)	89	11	157	8	136	vs 12 d
Hydroxychloroquin			1.4 (-4.0,	29.9 (-154,						NO difference 11 d
e-BMG ⁶²	4.8	3.4	6.9)	80.6)	69	4	83	5	148	vs 12 d
Hydroxychloroquin			-2.0 (-	-73.8 (-481.6,						
e-Utah ⁶³	2.6	4.6	6.2, 2.2)	48.0)	-51	4	151	7	152	6 d to 6 d
Hydroxychloroquin			0 (-6.5,	0 (-1447,						
e/Azithromycin-			6.5)	93.5)						
Brazil ⁶⁴	2.4	2.4	0.5)	93.3)	100	1	42	1	42	
										Yes mild illness (13
										d vs 18 d, p=0.01),
Nitazoxanide-			2.0 (-0.4,	78.8 (-79.7,						NO difference for
Romark ²²	2.6	0.5	4.5)	97.5)	49	5	195	1	184	moderate illness
Colchicine-			1.2 (-0.1,	20.0 (-2.8,						
COLCORONA ²⁰	5.8	4.7	2.5)	37.7)	86	131	2253	104	2235	Not reported
Losartan-MN ⁶⁵			-3.5 (-	-205 (-2749,						
	1.7	5.2	10.1, 3.1)	67.3)	-29	1	59	3	58	
			2.9 (-2.7,							NO difference 12 d
Niclosamide ⁶⁶	2.9	0.0	8.6)	1 (1, 1)	34	1	34	0	33	vs 15 d
Aspirin-ACTIV-			0.04 (-	5.6 (-1395,						
$4B^{67}$	0.7	0.7	1.9, 2.0)	94)	2448	1	136	1	144	Not reported
2.5-mg apixaban-			-0.01 (-	-0.7 (-1494,						
ACTIV-4B ⁶⁷	0.7	0.7	2.0, 2.0)	93.6)	-18360	1	136	1	135	Not reported
5-mg apixaban			-0.7 (-	-90.2 (-1974,						•
ACTIV-4B ⁶⁷	0.7	1.4	3.1, 1.7)	82.6)	-151	1	136	2	143	Not reported
	411		11.7 (1.1,	39.7 (3.5,						
Sulodexide ⁶⁸	29.4	17.7	22.3)	62.3)	9	35	119	22	124	Not reported
Enoxaparin-		17.77	-0.9 (-	-8.6 (-131,			117		12.	Troctoperiou
ETHIC ⁶⁹	10.5	11.4	9.2, 7.4)	49.0)	-111	12	114	12	105	Not reported
ZIIII	10.0	1111	-0.1 (-	-1.7 (-166,	111	1-	111	12	100	Trest Top Street
Enoxaparin-OVID ⁷⁰	3.4	3.4	3.3, 3.2)	61.2)	-1740	8	238	8	234	Not reported
Inhaled Ciclesonide-	3.1	3.1	3.3, 3.2)	01.2)	1710		230		231	1.00 Tepoticu
COVIS ⁷¹			1.8 (-1.4,	51.4 (-85.2,						
COVIS	3.4	1.7	4.9)	87.2)	56	7	203	3	179	19 d to 19 d
	J. 4	1./	7.7]	01.4)	50	1	203	J	1/7	17 U W 17 U

		1	1	I	I	1	1	1		
Inhaled ciclesonide-			-1.5 (-	-13.5 (-134,						NO difference 13 d
COVERAGE ⁷²	11.2	12.7	10.1, 7.1)	45.0)	-66	12	107	14	110	vs 12 d
			-2.6 (-	-43.7 (-471.4,						
Zinc ⁷³	6.0	8.6	12.4, 7.2)	63.9)	-38	3	50	5	58	11 dto 10 d
			1.8 (-6.8,	30.6 (-297.6,						
Ascorbic acid ⁷³	6.0	4.2	10.5)	87.9)	55	3	50	2	48	12 d to 10 d
			-6.1 (-	-101.1 (-637,						
Zinc/Ascorbic acid ⁷³	6.0	12.1	16.7, 4.6)	45.1)	-16	3	50	7	58	10 d too 10 d
Homeopathy-			4.4 (-4.3,	65.1 (-222.6,						
COVID-Simile ⁷⁴	6.8	2.4	13.2)	96.2)	23	3	44	1	42	
			28.6							
			(16.7,							YES 9d vs 14 d
Saliravira ⁷⁵	28.6	0.0	40.4)	1 (1, 1)	4	16	56	0	87	p<0.05
Azithromycin-			1.2 (-5.9,	10.5 (-72.3,						
Atomic2 ⁷⁶	11.6	10.3	8.4)	53.6)	82	17	147	15	145	Not reported
Azithromycin-			-4.0 (-							No difference
ACTION ²⁸	0.0	4.0	7.4, -0.6)	NA	-25	0	72	5	125	resolution day 14
			4.0 (-3.6,	66.7 (-210,						
Resveratrol ⁷⁷	6.0	2.0	11.6)	96.4)	25	3	50	1	50	Not reported

Table 2 Summary of historical efficacy of different therapeutics against SARS-CoV-2 VOCs. White = drug not available at that time; green = effective; orange = partially effective; red= not effective. Restriction reported refer to initial restrictions by FDA. NNT: number needed to treat.

	approximate	average NNT	cost to prevent a	efficacy	efficacy	efficacy	efficacy	efficacy	efficacy
	cost per	(sourced from	single	against	against	against	against	against	against
	patient	Table 2)	hospitalisation (€)	VOC Alpha	VOC	VOC BA.1	VOC	BA.4/5	BQ.1.1
					Delta		BA.2		
bamlanivimab+etesesevimab	2000	21	42,000		restricted				
					04/2021				
casirivimab+imdevimab	2000	30	60,000			restricted			
						01/2022			

sotrovimab	1000	22	22,000		restricted 03/2022	
tixagevimab+cilgavimab	1000	22	22,000			restricted 10/22
regdanvimab	300	23	6,900			
bebtelovimab	2000	Not calculated (low-risk pts)	Not calculated (low-risk pts)			
nirmatrelvir	635 (5 days)	18	11,435			
molnupiravir	635 (5 days))	34	21,590			
remdesivir	1600 (3 days)	22 (MOVE- Out)	35,200			
ССР	200 (600-ml)	31	6,200			
Vax-CCP						

Appendix for

Outpatient regimens to reduce COVID-19 hospitalizations: a systematic review and meta-analysis of randomized controlled trials.

David J. Sullivan, Daniele Focosi, Daniel F. Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth

Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD USA (Prof. D J Sullivan M.D., Prof. A Casadevall M.D.PhD,); North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy (Prof. D Focosi, M.D.); Johns Hopkins University School of Medicine Department of Neurology, Brain Injury Outcomes Division, Baltimore, MD, USA (Prof. D F Hanley M.D., J Ou M.S.); Division of Hematology, Carlo Poma Hospital, Mantua, Italy (Prof. M Cruciani M.D., Prof. M Franchini M.D.,); Departments of Epidemiology & Biostatistics and Pediatrics & Human Development, College of Human Medicine, Michigan State University, East Lansing, MI, USA (Prof. N Paneth, M.D., M.P.H)

Corresponding author. E-mail:dsulliv7@jhmi.edu

The PDF file includes:

Description of trial participants 2 **Appendix Figures** Appendix Figure 1: Symptom onset to enrollment 3 Appendix Figure 2: Odds ratio for hospitalizations from all interventions 4 Appendix Figure 3: Odds ratio for hospitalizations within CCP group 5 6 Appendix Figure 4: Risk of bias by RCT Appendix Figure 5: Funnel plots by RCTs class 7 **Appendix Tables** Appendix Table 1a: Participant characteristics Demographic and clinical characteristics 8 Appendix Table 1b: Participant characteristics Geography, age symptom onset 14 Appendix Table 2: Summary of findings table. GRADE evaluation by RCT 21 Appendix Table 2: Hospitalized Odds Ratio statistics 28 Appendix Table 4: Deaths during RCTs 31 **Appendix References** 35

Description of trial participants

The median age of participants was about 50 years. The CCP group had a nonweighted trial average of median age equal to 58 years, while the anti-Spike mAbs, small molecule antivirals and repurposed drug groups younger average of median age was equal to 45 to 48 years. Most RCTs had more women than men, and 84% of all RCT 60,043 participants had Caucasian ethnicity (Table 1, Appendix Table 2).


The individual RCTs differed in the percentage of participants with risk factors for progression to severe COVID-19. Of the 37 RCTs reporting aggregated hospitalization risk factors, ten had 100% of participants with at least one hospitalization risk factor, while 5 had fewer than 50%. The bebtelovimab placebo-controlled RCT explicitly focused exclusively on low-risk individuals ¹. Individual risk factors such as diabetes mellitus occurred in 10 to 20% of participants in most RCTs. Obesity with BMI over 29 averaged near 40% of RCT participants in the 4 therapy groups after excluding the large single 25,000 molnupiravir-PANORAMIC RCT with 15% of participants with BMI's over 30 (Table 1) ²⁵.

Of 18 RCTs reporting seropositivity rates at baseline, 11 had < 25% screening seropositive (Table 1, Figure 2). The molnupiravir-PANORAMIC RCT was an outlier, with 98% participant seropositives²⁵. All but one² of the RCTs enrolled within 8 days (median) of symptom onset. In RCTs of anti-Spike mAbs and small molecule antivirals, median time from illness onset to intervention was 3.5 to 4 days (Figure 3, Table 1, Appendix Table 2). CCP and repurposed antiviral drug RCTs enrolled within 4.5 to 5.1 days from symptom onset.

The CCP RCTs were conducted in the USA^{3,4}, Argentina⁵, Netherlands⁶ and Spain⁷ (Appendix Table 2). The anti-Spike mAb RCTs all had a USA component, but were largely centered in the Americas except for the sotrovimab RCT, which took place in Spain⁸. Many of the repurposed drugs and nirmatrelvir/ritonavir RCTs recruited worldwide⁹.

Four of the five CCP RCTs (COV-Early⁶, CONV-ERT⁷, Argentina⁵ and C3PO⁴), and all eight anti-Spike mAb RCTs took place in the setting of the D614G variant and the Alpha VOC (Figure 2). By contrast, most of the molnupiravir, nirmatrelvir/ritonavir⁹ and interferon lambda RCTs were conducted in the setting of the Delta VOC. The ivermectin¹⁰ and fluvoxamine¹¹ RCTs ended as the Delta VOC wave began in August 2021. The remdesivir RCT spanned D614G, Alpha and Beta VOC but missed Delta¹². The CSSC-004 RCT of CCP was the longest RCT reviewed, spanning periods characterized by D614G to Delta VOC infections³.

Comparison of mean interval from symptom onset to enrollment/intervention as well as per protocol interval inclusion limit for all participants.



Appendix Figure 2: Odds ratio for hospitalizations from all interventions.

Therapeutic interventions ordered according to mechanism of action (CCP, anti-Spike mAbs, small molecule antivirals and repurposed drugs

Study		ention Total	C Events	ontrol Total	Odds Ratio	OR	95%-CI	Weight
CCP-CONV-ERT	22	188	21	188		1.05	[0.56; 1.99]	2.5%
CCP-COV-Early	12	202		204	-	0.61	[0.29; 1.30]	2.2%
CCP-C3PO	52	257	56	254	- 4	0.90	[0.59; 1.37]	3.0%
CCP-Argentina	13	80	25	80		0.43	[0.20; 0.91]	2.1%
CCP-CSSC-004	17	592		589	-	0.44	[0.25; 0.79]	2.6%
Bamlanivimab-BLAZE-1 Sotrovimab-COMET-ICE	5 6	309 528	9 30	143 529		0.24	[0.08; 0.74] [0.08; 0.46]	1.4% 1.9%
Bamlanivimab/etesevimab-BLAZE-1	11	518	36	517		0.19	[0.05, 0.40]	2.3%
Casirivimab/imdevimab-REGEN-COV Ph 3	18	1355	62	1341		0.28	[0.16; 0.47]	2.7%
Casirivimab/imdevimab-REGEN-COV Ph 1/2	3	533	5	266		0.30	[0.07; 1.25]	1.0%
Bebtelovimab-BLAZE-4	2	125	2	128		1.02	[0.14; 7.39]	0.6%
Regdanvimab-CT-P59	9	203	9	104	_ *	0.49	[0.19; 1.27]	1.7%
Regdanvimab-CT-P59-2 Tixaqevimab-cilqavimab-TACKLE	16 18	656 407	52 37	659 415		0.29 0.47	[0.16; 0.52] [0.26; 0.84]	2.6% 2.6%
Molnupiravir–MOVe–OUT	48	709	68	699		0.47	[0.46; 0.99]	3.1%
Molnupiravir–PANORAMIC		12516		12484	T +	1.07	[0.81; 1.42]	3.4%
Molnupiravir-Aurobindo	0	610	0	610			,	0.0%
Nirmatrelvir/ritonavir-EPIC-HR	8	1039	66	1046		0.12	[0.06; 0.24]	2.2%
Remdesivir-PINETREE	2	279	15	283	-	0.13	[0.03; 0.57]	1.0%
Interferon Lambda-TOGETHER	21	931	40	1018		0.56	[0.33; 0.96]	2.7%
Interferon Lambda- ILIAD Interferon Lambda-COVID-Lambda	1 2	30 60	1 2	30 60		1.00	[0.06; 16.76] [0.14; 7.34]	0.3% 0.6%
Sofosbuvir and daclatasvir–SOVODAK	1	27	4	28		0.23	[0.14, 7.34]	0.5%
Favipavir–Avi–Mild–19	6	112		119		3.31	[0.65; 16.76]	0.9%
Favipiravir-Iran	4	38	2	39			[0.37; 12.65]	0.8%
Favipiravir-FLARE	1	59	0	60	- + -	→ 3.10	[0.12; 77.71]	0.3%
Favipiravir/Lopinavir/Ritonavir-FLARE	1	61	0	60		→ 3.00	[0.12; 75.11]	0.3%
Lopinavir/Ritonavir-FLARE	1 7	60 220	0 6	60		→ 3.05 1.01	[0.12; 76.39]	0.3%
Lopinavir/ritonavir–TREAT NOW Lopinavir/ritonavir–TOGETHER	14	244	11	226 227		1.21 1.20	[0.40; 3.64] [0.53; 2.69]	1.5% 2.0%
Tenofovir Disproxil Fumarate Plus Emtricitabine–AR0–CORONA	2	30	1	30		→ 2.07	[0.18; 24.15]	0.4%
Metformin-COVID-OUT	8	596	19	601		0.42	[0.18; 0.96]	2.0%
Metformin –TOGETHER	24	215	24	203		0.94	[0.51; 1.71]	2.5%
Fluvoxamine-TOGETHER	75	741	97	756	=	0.77	[0.56; 1.05]	3.3%
Fluvoxamine-STOP COVID	0	80	6	72	<	0.06	[0.00; 1.15]	0.3%
Fluvoxamine-COVID-OUT Fluvoxamine ACTIV-6	6 1	299 670	5 2	293 607		1.18 0.45	[0.36; 3.91] [0.04; 5.00]	1.3% 0.4%
Fluvoxamine/budesonide-TOGETHER	7	738	8	738		0.43	[0.04, 5.00]	1.6%
Ivermectin-TOGETHER	79	679	95	679	-	0.81	[0.59; 1.11]	3.3%
Ivermectin-COVID-OUT	4	374	5	356		0.76	[0.20; 2.85]	1.2%
Ivermectin Iran	19	268	14	281	+-	1.46	[0.71; 2.96]	2.3%
Ivermectin–ACTIV–6	10	817	9	774		1.05	[0.43; 2.61]	1.8%
Ivermectin high dose–ACTIV–6 Hydroxychloroquine–TOGETHER	5 8	602 214	2 11	604 227		2.52 0.76	[0.49; 13.04] [0.30; 1.93]	0.8% 1.8%
Hydroxychloroquine-TOGETHEN Hydroxychloroquine-COVID-19 PEP	5	214		211		0.76	[0.30, 1.93]	1.5%
Hydroxychloroquine –AH COVID–19	4	111	0	37		→ 3.14	[0.17; 59.70]	0.3%
Hydroxychloroquine-BCN PEP-CoV-2	8	136	11	157		0.83	[0.32; 2.13]	1.7%
Hydroxychloroquine-BMG	5	148	4	83		0.69	[0.18; 2.65]	1.1%
Hydroxychloroquine-Utah	7	152		151	*	1.77	[0.51; 6.19]	1.2%
Hydroxychloroquine/Azithromycin–Brazil	1	42 184	1 5	42 195		1.00	[0.06; 16.53]	0.3%
Nitazoxanide-Romark Colchicine-COLCORONA	104	2235	131	2253		0.21 0.79	[0.02; 1.79] [0.61; 1.03]	0.5% 3.4%
Losartan-MN	3	58	1	59		→ 3.16	[0.32; 31.34]	0.5%
Niclosamide	0	33	1	34		0.33	[0.01; 8.48]	0.3%
Aspirin–ACTIV–4B	1	144		136	-	0.94	[0.06; 15.24]	0.3%
2.5-mg apixaban-ACTIV-4B	1	135		136		1.01	[0.06; 16.27]	0.3%
5-mg apixaban ACTIV-4B	2	143	1	136		→ 1.91 0.50	[0.17; 21.36]	0.4%
Sulodexide	22 12	124 105	35 12	119 114		0.52	[0.28; 0.95] [0.47; 2.56]	2.5% 1.9%
Enoxaparin-ETHIC Enoxaparin-OVID	8	234		238		1.02		1.6%
Inhaled Ciclesonide-COVIS	3	179		203		0.48	[0.12; 1.87]	1.1%
Inhaled ciclesonide-COVERAGE	14	110	12	107		1.15	[0.51; 2.63]	2.0%
Zinc	5	58		50		1.48	[0.34; 6.52]	1.0%
Ascorbic acid	2	48		50	-	0.68	[0.11; 4.27]	0.7%
Zinc/Ascorbic acid	7	58		50		2.15	[0.53; 8.80]	1.1%
Homeopathy-COVID-Simile Saliravira	1	42 87		44 56		0.33	[0.03; 3.34] [0.00; 0.24]	0.5% 0.3%
Azithromycin–Atomic2	15	145		147		0.88	[0.42; 1.84]	2.2%
Azithromycin–ACTION	5	125		72			[0.36; 121.45]	0.3%
Resveratrol	1	50		50			[0.03; 3.18]	0.5%
Random effects model	ana	34369	1304	33617	•	0.67	[0.57; 0.80]	100.0%
Heterogeneity: $I^2 = 52\%$, $\tau^2 = 0.2038$, $p < 0.01$	303	J-1003	1004			7	[0.07, 0.00]	. 30.0 /8
Test for overall effect: $z = -4.57 (p < 0.01)$				0.0	05 0.5 1 2 10	20		

A) Fixed and random effect model

	Interve	ention	C	ontrol				Weight	Weight
Study	Events	Total	Events	Total	Odds Ratio	OR	95% - CI	(common)	(random)
CCP-CONV-ERT	22	188	21	188	+	1.05	[0.56; 1.99]	15.8%	22.6%
CCP-CoV-Early	12	202	19	204		0.61	[0.29; 1.30]	15.2%	18.2%
CCP-C3PO	52	257	56	254		0.90	[0.59; 1.37]	38.3%	34.2%
CCP-CSSC-004	17	592	37	589		0.44	[0.25; 0.79]	30.7%	24.9%
Common effect model	103	1239	133	1235	4	0.74	[0.56; 0.97]	100.0%	
Random effects mode	l					0.73	[0.49; 1.07]		100.0%
Heterogeneity: $I^2 = 42\%$, τ	$^{2} = 0.0667$	p = 0.	16	Г					
Test for overall effect (com				0.030.0	0.5 1 2 10	0 20			
Test for overall effect (rand	om effects	s): z = -	1.61 (p =	0.11)					

B) Fixed and random effect model

Study	Interve Events		Co Events	ontrol Total	Odds Ratio	OR	95%-CI	Weight (common) (Weight random)
CCP-CoV-Early	12	202	19	204		0.61	[0.29; 1.30]	14.9%	19.3%
CCP-C3PO	52	257	56	254] 	0.90	[0.59; 1.37]	37.5%	35.5%
CCP-Argentina	13	80	25	80			[0.20; 0.91]	17.5%	19.0%
CCP-CSSC-004	17	592	37	589		0.44	[0.25; 0.79]	30.1%	26.2%
Common effect model	94	1131	137	1127	-	0.64	[0.48; 0.85]	100.0%	
Random effects mode					-	0.60	[0.40; 0.90]		100.0%
Heterogeneity: $I^2 = 41\%$, τ	$^{2} = 0.0722$	p = 0.1	17						
Test for overall effect (com				0.01)0.0	0.5 1 2 10	0 20			
Test for overall effect (rand	om effects	s): z = -2	2.47 (p =	0.01)					

C) Fixed and random effect model

Study	Interve Events		Co Events	ontrol Total	Odds Ratio	OR	95% - CI	Weight (common)	Weight (random)
CCP-CONV-ERT CCP-CoV-Early CCP-C3PO CCP-Argentina CCP-CSSC-004	22 12 52 13 21		21 19 56 25 40	188 204 254 80 589		0.61 0.90 0.43	[0.56; 1.99] [0.29; 1.30] [0.59; 1.37] [0.20; 0.91] [0.29; 0.87]	12.6% 31.9% 14.9%	18.5% 14.6% 29.7% 14.3% 22.8%
Common effect model Random effects model Heterogeneity: $I^2 = 34\%$, τ^2 Test for overall effect (commost for overall effect (random	= 0.0489 non effect): z = -	.20 2.68 (p <	,	0.5 1 2 10		[0.55; 0.91] [0.50; 0.96]		100.0%

Appendix Figure 4: Risk of bias by RCT

	iluix Figure 4. N							,
			Deviations from	Missing		Selection of the		
		Radomization	intended	outcome data	Mesaurement of	reported results	Highest risk of	
TYPE	Study	process bias	intervention bias	bias	the outcome bias	bias	bias	ROB Source
Ab-CCP	CCP-CONV-ert	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
Ab-CCP	CCP-COV-early	Low	Low	Low	Low	Low	Low	pending in NMA-COVID
Ab-CCP	CCP-C3PO	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
Ab-CCP	CCP-Argentina	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
Ab-CCP	CCP-CSSC-004	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
mAb	Bamlanivimab-BLAZE-1	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
mAb	Sotrovimab-COMET-ICE	Low	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
mAb	Bamlanivimab/etesevimab-BLAZE-1	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
mAb	Casirivimab/imdevimab-REGEN-COV Ph 3	Some concerns	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
	Casirivimab/imdevimab-REGEN-COV Ph							
mAb	1/2	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
mAb	Bebtelovimab-BLAZE-4	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
mAb	Regdanvimab-CT-P59	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
mAb	Regdanvimab-CT-P59-2	Low	Some concerns	Low	Low	Low	Some concerns	https://covid-nma.com/
mAb	Tixagevimab-cilgavimab-TACKLE	Low	Some concerns	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
SMA	Molnupiravir-MOVe-OUT	Low	Low	Low	Low	Low	Low	https://covid-nma.com/
SMA	Molnupiravir-PANORAMIC	Low	Some concerns	HIGH	Some concerns	Low	HIGH	https://covid-nma.com/
SMA	Molnupiravir-Aurobindo	Low	Low	Low	Some concerns	Some concerns	Some concerns	https://covid-nma.com/
SMA	Nirmatrelvir/ritonavir-EPIC-HR	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
SMA	Remdesivir-PINETREE	Some concerns	Low	Low	Low	Low	Some concerns	https://covid-nma.com/
	1							RevMan pending in NMA-
SMA	Interferon Lambda-TOGETHER	Low	Low	Low	Low	Low	Low	COVID
SMA	Interferon Lambda- ILIAD	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
SMA	Interferon Lambda-COVID	Low	Low	Low	Low	Some concerns	Some concerns	https://covid-nma.com/
	1	little evidence to	little evidence to	little evidence to	little evidence to	little evidence to	little evidence to	
SMA	Sofosbuvir & daclatasvir-SOVODAK	score	score	score	score	score	score	https://covid-nma.com/
SMA	Favipiravir-Avi-Mild-19	Low	Low	Low	Some concerns	Low	Some concerns	https://covid-nma.com/
								RevMan pending in NMA-
SMA	Favipiravir-Iran	Low	Low	Low	Low	Low	Low	COVID
SMA	Favipiravir-FLARE	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
SMA	Favipiravir/Lopinavir/Ritonavir-FLARE	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
SMA	Lopinavir/Ritonavir-FLARE	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
	1							RevMan pending in NMA-
SMA	Lopinavir/ritonavir-TREAT NOW	Low	Low	Some concerns	Low	Low	Some concerns	COVID
SMA	Lopinavir/ritonavir-TOGETHER	Low	Low	Some concerns	Low	Some concerns	Some concerns	https://covid-nma.com/
								RevMan pending in NMA-
SMA	Tenofovir/Emtricitabine-AR0-CORONA	Low	HIGH	Low	Unclear	Low	HIGH	COVID
DIVILLE	Tenorova Estationalo Perto Corto	Lon	111011	2011	Cheleu	Lon		RevMan pending in NMA-
RP	Metformin-COVID-OUT	Low	Low	Unclear	Low	Low	Low	COVID
KI	Wederman-covib-oci	Low	Low	Circical	Low	Low	LOW	RevMan pending in NMA-
RP	metformin -TOGETHER 2	Low	Low	Low	Low	Low	Low	COVID
RP	Fluvoxamine-TOGETHER	Low	Some concerns	Low	Low	Low	Some concerns	https://covid-nma.com/
RP	Fluvoxamine -STOP COVID	Low	Low	Some concerns	Low	Low	Some concerns	https://covid-nma.com/
Kr	Filivoxammie -STOF COVID	Low	Low	Some concerns	LOW	LOW	Some concerns	RevMan pending in NMA-
RP	Fluvoxamine-COVID-OUT	Low	Low	Unclear	Low	Low	Low	COVID
KI	Travoxamino-CO v 15-OC 1	Low	Low	Circical	LOW	Low	LOW	
D D	El	r	Y	Hadee	Y	Y	TT1	RevMan pending in NMA-
RP	Fluvoxamine-ACTIV-6	Low	Low	Unclear	Low	Low	Unclear	COVID
								COVID RevMan pending in NMA-
RP RP	Fluvoxamine-ACTIV-6 Fluvoxamine/budesonide-TOGETHER	Low	Low	Unclear Unclear	Low	Low	Unclear	COVID RevMan pending in NMA- COVID
RP	Fluvoxamine/budesonide-TOGETHER	Low	Low	Unclear	Low	Low	Unclear	COVID RevMan pending in NMA- COVID RevMan pending in NMA-
								COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID
RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER	Low	Low	Unclear	Low	Low	Unclear Low	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA-
RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT	Low Low	Low Low	Unclear Unclear Unclear	Low Low	Low Low	Unclear Low Unclear	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID
RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER	Low	Low	Unclear	Low	Low	Unclear Low	COVID RevMan pending in NMA-COVID RevMan pending in NMA-COVID RevMan pending in NMA-COVID pending in NMA-COVID
RP RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran	Low Low Low	Low Low Low Low	Unclear Unclear Low	Low Low Low Unclear	Low Low Low Low	Unclear Low Unclear Unclear	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID pending in NMA- COVID RevMan pending in NMA- NMA- RevMan pending in NMA-
RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT	Low Low	Low Low	Unclear Unclear Unclear	Low Low	Low Low	Unclear Low Unclear	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID
RP RP RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6	Low Low Low Low Low	Low Low Low Low Low	Unclear Unclear Low Low	Low Low Unclear Low	Low Low Low Low	Unclear Low Unclear Unclear Unclear	COVID RevMan pending in NMA- COVID
RP RP RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6	Low Low Low Low Low Low	Low Low Low Low Low	Unclear Unclear Low Low	Low Low Unclear Low Unclear	Low Low Low Low Low	Unclear Low Unclear Unclear Unclear Low	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID Pending in NMA- COVID RevMan pending in NMA- COVID
RP RP RP RP RP	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER	Low Low Low Low Low Low Low	Low Low Low Low Low Low Low Low	Unclear Unclear Low Low Low Some concerns	Low Low Unclear Low Unclear Low	Low Low Low Low Low Low Low Some concerns	Unclear Low Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID pending in NMA-COVID RevMan pending in NMA- COVID
RP RP RP RP RP RP	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP	Low Low Low Low Low Low Some concerns	Low Low Low Low Low Low Low Low	Unclear Unclear Low Low Low Some concerns Some concerns	Low Low Unclear Low Unclear Low Low Low Low Low	Low	Unclear Unclear Unclear Unclear Unclear Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/
RP RP RP RP RP RP RP	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Idydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-AEOVID-19 PEP Hydroxychloroquine-AEOVID-19 PEP Hydroxychloroquine-AEOVID-19	Low Low Low Low Low Low Some concerns Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns	Low Low Unclear Low Unclear Low Low Low Low Low	Low Low Low Low Low Low Low Some concerns Low	Unclear Unclear Unclear Unclear Unclear Some concerns Some concerns	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID Pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/
RP RP RP RP RP RP	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-BCVID-19 PEP Hydroxychloroquine-BCVID-19 Hydroxychloroquine-BCN PEP-CoV-2	Low	Low	Unclear Unclear Low Low Some concerns Low Some concerns Low Some concerns	Low Low Unclear Low Unclear Low Low Low Low Low Some concerns	Low Low Low Low Low Some concerns Low Some concerns Some concerns	Unclear Unclear Unclear Unclear Unclear Some concerns	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID pending in NMA-COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
RP RP RP RP RP RP RP	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Idydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-AEOVID-19 PEP Hydroxychloroquine-AEOVID-19 PEP Hydroxychloroquine-AEOVID-19	Low Low Low Low Low Low Some concerns Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns	Low Low Unclear Low Unclear Low Low Low Low Low	Low Low Low Low Low Low Low Some concerns Low	Unclear Unclear Unclear Unclear Unclear Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
RP	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Ilydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG	Low	Low	Unclear Unclear Low Low Some concerns Low Some concerns Low Some concerns	Low Low Unclear Low Unclear Low Unclear Low Low Low Low Low Low Low Low Low	Low Low Low Low Some concerns Low Some concerns Some concerns	Unclear Unclear Unclear Unclear Unclear Some concerns Some concerns	COVID RevMan pending in NMA- COVID RevMan pending in NMA- COVID Pending in NMA- COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ RevMan pending in NMA-
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-ACVID-19 PEP Hydroxychloroquine-AH COVID-19 Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Some concerns Low Some concerns High	Low Low Unclear Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns	Unclear Low Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ RevMan pending in NMA- COVID
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-GOVID-19 PEP Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Main-Mydroxychloroquine-Mydroxychloroquine-	Low Low Low Low Low Low Some concerns Low Low Some concerns Low Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns	Unclear Low Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin-I	Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-AH COVID-19 Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Ibah	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns Low Low Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns	Unclear Low Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Althromycin-Brazil Nitazoxanide-Romark Colehicine-COLCORONA Losartan-MN	Low	Low	Unclear Unclear Low Low Low Some concerns Low Some concerns Low Some concerns Low Some concerns Low	Low Low Unclear Low Unclear Low	Low Low Low Low Low Low Some concerns Low	Unclear Unclear Unclear Unclear Low Some concerns Low Low Low Low Low Low Low Lo	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Utah Hydroxychloroquine-Utah Hydroxychloroquine-Warin-Brazil Nitazoxanide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide	Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/ https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP Hydroxychloroquine-AH COVID-19 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Brazil Nitazoxamide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide Aspirin-ACTIV-4B	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Low Unclear Unclear Unclear Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxamine/budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Low Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID RevMan pen	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin-I	Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID RevMan pen
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP Hydroxychloroquine-AH COVID-19 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Brazil Nitazoxamide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Low Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-COVID-19 PEP Hydroxychloroquine-AH COVID-19 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Brazil Nitazoxamide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B S-mg apixaban ACTIV-4B Sulodexide	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Some concerns Low Some concerns Low Some concerns Some concerns Low Low Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxaminebudesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran	Low	Low	Unclear Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-BMG Hydroxychloroquine-BM	Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Some concerns Low Some concerns Low Some concerns Low Low Some concerns Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- COVID
RP R	Fluvoxaminebudesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran	Low	Low	Unclear Unclear Low Low Some concerns Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Low Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns High Some concerns Some concerns High Some concerns	COVID RevMan pending in NMA-COVID https://covid-nma.com/
RP R	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Low Low Low Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns Low Low Low Low Low Low Low Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns Low Some concerns Some concerns Some concerns Some concerns Some concerns Some concerns Low Some concerns Low Some concerns Some concerns High Some concerns Some concerns Some concerns	COVID RevMan pending in NMA- COVID https://covid-nma.com/	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-BCOVID-19 PEP Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-Brazil Nitazoxanide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban-ACTIV-4B Sulodexide Enoxaparin-ETHIC Enoxaparin-OVID Inhaled Ciclesonide-COVIS Inhaled ciclesonide-COVERAGE Zine	Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns Low Some concerns Low Low Low Low Some concerns Low	Low Low Unclear Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA-COVID https://covid-nma.com/
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Low Some concerns Low Some concerns Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns High Some concerns High Some concerns	COVID RevMan pending in NMA-COVID https://covid-nma.com/	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Low Low Low Some concerns Some concerns Low Some concerns Low Some concerns Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Low Some concerns Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns High Some concerns High Some concerns	COVID RevMan pending in NMA-COVID RevMan pending in NMA-CO	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin high dose-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-OVID-19 PEP Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BCN PEP-CoV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Nitazoxanide-Romark Colchicine-COLCORONA Losartan-MN Niclosamide Aspirin-ACTIV-4B 2.5-mg apixaban ACTIV-4B 3-mg apixaban ACTIV-4B Sulodexide Enoxaparin-UID Inhaled Ciclesonide-COVIS Inhaled ciclesonide-COVERAGE Zine Ascorbic acid Zine/Ascorbic acid	Low	Low	Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Low Some concerns Low Low Some concerns Low Low Low Some concerns Low Low Some concerns Low Low Some concerns Low Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Low Unclear Unclear Unclear Unclear Low Some concerns	COVID RevMan pending in NMA- RevMan pending in NMA- COVID
RP R	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Ivermectin-ACTIV-6 Ivermectin high dose-ACTIV-6 Hydroxychloroquine-TOGETHER Hydroxychloroquine-TOGETHER Hydroxychloroquine-BCN PEP-COV-2 Hydroxychloroquine-BCN PEP-COV-2 Hydroxychloroquine-BCN PEP-COV-2 Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BMG Hydroxychloroquine-BNBG Hydroxychloroquine-BN	Low	Low	Unclear Unclear Unclear Low Low Low Some concerns Some concerns Some concerns High Some concerns Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Low Some concerns Low Some concerns Some concerns Low Some concerns Low Some concerns Low Some concerns Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns High Some concerns	COVID RevMan pending in NMA- COVID
RP R	Fluvoxamine budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Unclear Low Low Some concerns Some concerns Some concerns Some concerns Some concerns Low Some concerns	Low Low Unclear Low	Low Low Low Low Low Low Some concerns Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Low Some concerns Low Some concerns Low Some concerns Some concerns	COVID RevMan pending in NMA- RevMan pending in NMA- COVID	
RP R	Fluvoxamine-budesonide-TOGETHER Ivermectin-TOGETHER Ivermectin-COVID-OUT Ivermectin Iran Low	Low	Unclear Unclear Unclear Low Low Low Some concerns Low Some concerns Low Some concerns Low Some concerns Some concerns Low	Low Low Unclear Low	Low Low Low Low Low Low Low Some concerns Some concerns Some concerns Low	Unclear Unclear Unclear Unclear Unclear Unclear Low Some concerns Some concerns Some concerns Some concerns Some concerns Low Some concerns Some concerns Some concerns Low Some concerns Low Some concerns High Some concerns Some concerns Low Some concerns Low Some concerns High Some concerns Some concerns Some concerns Some concerns	COVID RevMan pending in NMA-COVID RevMan-Rev	

Appendix Figure 5: Funnel plots by RCTs class

A) CCP, B) anti-Spike mAbs C) small molecule antivirals and D) repurposed drugs. For anti-Spike mAbs RCTs, there is a suggestion of missing studies on the right side of the plot, where results would be unfavourable to the experimental intervention, for which either very high efficacy of high-dose anti-Spike mAbs or non-reporting bias is a plausible explanation.




 Table 1a

 Demographic and clinical characteristics of recruits in the RCTs analyzed in this review.

Study	mIT T	medi an age (rang e)	total fema le n(%	Whi te n(%	Black n(%	Hispa nic n(%)	1 or more medical high risk condito ns for COVID -19 progessi on	diabet es n(%)	hypertens	obesit y or BMI > 30 n(%)	median duratio n sympto ms	Seropositive at baseline n(%)	Hospi tal type	Endpo int days for hosp
CCP (5 RCTs) totals or	263		1409	2213	266	862	2074	326		854				•
averages	4	58	(53)	(84)	(10)	(33)	(79)	(15)	606 (33)	(38)	4.5	73 (9)		
anti-Spike mAbs (8 RCTs)	742		3944	6214	455	3113	6562	1067		3197				
totals or averages	1	47	(53)	(84)	(6)	(42)	(88)	(14)	1249 (17)	(43)	3.5	1087 (15)		
Small molecule antivirals			1811	2872					, ,			25710 (77)		
(11 RCTs) totals or	331		6	6	399	2458	22400	3150		6271		{710/8148=9%		
averages	48	45.4	(55)	(87)	(1)	(7)	(68)	(10)	6954 (21)	(19)	4	w/o-Mol-Pan.)		
				1475										
Repurposed drugs (27	168		9595	2	815	4212	8669	2174		6615				
RCTs) totals or averages	40	48	(57)	(89)	(5)	(32)	(88)	(13)	4318 (27)	(46)	5.1	2303 (51)		
_			173			376		49	not				All	
CCP-CONV-ert ⁷	376	56	(46)	0	0	(100)	278 (74)	(13)	reported	96 (26)	4.4	43 (11)	cause	28-30
			187	406 (100				not report	not	not reporte	5 (iqr4-		All	
CCP-COV-Early ¹³	406	58	(46))	0	0	278 (68)	ed	reported	d	6)	30 (8)	cause	28-30
,			274	237	103	156	511	142	^	302	,	,	All	
CCP-C3PO ⁴	511	54	(54)	(46)	(20)	(31)	(100)	(28)	216 (42)	(59)	4	not reported	cause	15
CCP-Argentina ⁵	160	77 (65- 90+)	100 (62)	0	0	160 (100)	131 (82)	36 (23)	114 (71)	12 (8)	3	not reported	hypoxi a resp rate def	28-30
	118	43 (18-	675	934	163	170				444			COVI D-19	
CCP-CSSC-004 ³	1	85)	(57)	(79)	(14)	(14)	470 (40)	99 (8)	276 (23)	(38)	6	not reported	related	28-30

	1	1	ı	1	1	I	ı	1	<u> </u>		I	1	COLU	1
													COVI D-19	
		45											related	
		(18-	249	389	29	198			not	201			+ ED	
Bamlanivimab-BLAZE-1 ¹⁴	452	86)	(55)	(86)	(6)	(44)	310 (69)			(44)	4	mat mamantad	visit	28-30
Ballianivilliau-BLAZE-1	105	53(17	571	919	42	687	1055	233	reported not	665	4	not reported	All	20-30
Sotrovimab-COMET-ICE ⁸	7	-96)	(54)	(87)	(4)	(65)	(99.9)	(23)	reported	(63)	3	not reported	cause	28-30
Soutovillab-COMET-ICE	/	54	(34)	(07)	(4)	(03)	(99.9)	(23)	reported	(03)	3	not reported	COVI	26-30
Bamlanivimab/etesevimab-	103	(12-	538	896	83	304		285	not	median			D-19	
BLAZE-1 ¹⁵	5	77+)	(52)	(87)	(8)	(29)	983 (95)	(28)	reported	34 bmi	4	not reported	related	28-30
BLAZE-1	3	50	(32)	(67)	(6)	(29)	703 (73)	(20)	reported	34 UIII	7	not reported	Terateu	20-30
		(iqr											COVI	
Casirivimab/imdevimab-	269	39-	1407	2297	143	935	2696	412		1559			D-19	
REGEN-COV Ph 3 ¹⁶	6	50)	(52)	(85)	(5)	(35)	(100)	(15)	993 (37)	(58)	3	620 (23)	related	28-30
REGERVEOVING	0	42	(32)	(03)	(3)	(33)	(100)	(13)	773 (31)	(30)	3	020 (23)	Telatea	20 30
		(iqr]
Casirivimab/imdevimab-		31-	423	681	74	403				298			All	
REGEN-COV Ph 1/2 ¹⁷	799	52)	(53)	(85)	(9)	(50)	483 (61)			(37)	3	304 (38)	cause	28-30
		- /	()	()	(-)	()	(-)	not		()	_	()	COVI	
			135	187	48			report	not				D-19	
Bebtelovimab-BLAZE-4 ¹	253	34	(53)	(74)	(19)	91 (36)	0 (0)	ed	reported		3	27 (11)	related	28-30
		51				` `	, ,							
		(iqr40	166	286					not				All	
Regdanvimab-CT-P59 ¹⁸	307	-60)	(51)	(87)	0	27 (8)	226 (69)	29 (9)	reported	52 (16)	3	9 (3)	cause	28-30
		48												
Regdanvimab-CT-P59-2 ¹⁹	131	(iqr38	641	1132		276		120		415			all	
Reguanviniao-C1-F39-2		` *	_	_						-				
	5	-59)	(49)	(86)	7(1)	(21)	880 (67)	(9)	443 (34)	(32)	4	148 (11)	cause	28
m: : 1 · · · · ·		46 (1	455	550	26	460		100		200			COVI	
Tixagevimab–cilgavimab-	022	46 (sd	455	559	36	468	000 (00)	108	256 (20)	388	_	107 (14)	D-19	20.20
TACKLE ²⁰	822	15.2)	(50)	(62)	(4)	(52)	809 (90)	(12)	256 (28)	(43)	5	127 (14)	related	28-30
M.1. · · MOV	1.40	43	735	012	7.5	711	1.40.4	228		1056(7			A 11	
Molnupiravir-MOVe- OUT ²¹	140	(18-	(51.3	813	75	711	1424	(15.9)	not	1056(7	2	(20 (22)	All	28-30
0012	8	90) 57	1510	(56) 2427	(5)	(49)	(99.4)	%	reported	3)	3	620 (23) 25333 (98) 2+	cause	28-30
Malayainayin	250		1510	0	155		17759	2195		3912		` /	A11	
Molnupiravir- PANORAMIC ²²	00	(18- 99)	(59)	(94)	(0.6)		(69)	(9)%	5782 (22)	(15)%	3	doses of vaccine		28-30
ranorawic	00	36	(39)	1220	(0.0)		(09)	(9)70	3/02 (22)	(13)70	3	vaccine	cause	20-30
	122	(18-	468	(100									All	
Molnupiravir-Aurobindo ²³	0	60)	(38)	(100	0	0	90 (7.3)				3	not reported	cause	28-30
Monuphavii-Auroomuo	10	46	(30)	,	U	U	70 (7.3)	 	1	 	<i>J</i>	not reported	COVI	20-30
Nirmatrelvir/ritonavir-	208	(18-	1098	1607	110	1010	2085	252		744			D-19	
EPIC-HR ⁹	5	88)	(49)	(72)	(4.9)	(45)	(100)	(11)	739 (33)	(36)	3	27 (11)	related	28-30
EI IC-IIK	J	00)	(47)	(14)	(4.7)	(43)	(100)	(11)	137 (33)	(30)	J	21 (11)	retated	20-30

		50							I				COVI	
		(12-	269	452	42	235	562	346		310			D-19	
Remdesivir-PINETREE ¹²	562	77+)	(48)	(80)	(7.5)	(41)	(100)	(62)	268 (48)	(55)	5	9 (3)	related	28-30
		43											COVI	
Interferon Lambda-	194	(18-	1113	58	28	1853	1124	181		719			D-19	
TOGETHER ²⁴	9	92)	(57)	(3)	(1)	(95)	(58)	(9)	581 (30)	(37)	3	1107 (58) FV	related	28
		46	2.5										COVI	
Interferon Lambda- ILIAD ²⁵	60	(iqr32 -54)	35 (60)	31	6		9			12	5	5/51 (10)	D-19 related	14
ILIAD	00	36	(00)	31	0		9			12	3	3/31 (10)	Terated	14
Interferon Lambda-		(18-	50	33				12			5 (iqr3-		All	
COVID-Lambda ²⁶	120	71)	(42)	(28)		74 (63)		(10)	14 (12)		6)	49 (41)	cause	28-30
				55										
Sofosbuvir and daclatasvir-			29	(100							not		All	
SOVODAK ²⁷	55	<50 37	(53))					-		reported	not reported	cause	28-30
		(iqr32	76	231 (100				25					All	
Favipavir-Avi-Mild-19 ²⁸	231	(1q132 -44)	(33)	(100	0	0		(11)	14 (6)	39 (17)	3	not reported	cause	28-30
Tavipavii 71VI Willa 19	231	11)	(33)	77	Ü	V		(11)	11(0)	37 (17)	3	not reported	cause	20 30
				(100									all	
D		4.1		(100			11 (14)				_			20
Favipiravir-Iran ²⁹	77	41	34)	0	0	11 (14)	nr	nr	nr	4		cause	28
			56	98									all	
Favipiravir-FLARE ³⁰	119	40	(47)	(82)			17 (14)			20 (17)	nr	74 (62)	cause	28
Favipiravir/Lopinavir/Riton			59	99									all	
avir-FLARE ³⁰	121	40	(49)	(82)			19 (16)			20 (17)	nr	77 (64)	cause	28
Lopinavir/Ritonavir-			60	98									all	
FLARE ³⁰	120	40	(50)	(82)			16 (13)			20 (17)	nr	74 (62)	cause	28
		41	(00)	(=)			- ()			= (= ,)		7 1 (=)		
Lopinavir/ritonavir-		(19-	261	354	35					149			All	
TREAT NOW ³¹	446	75)	(59)	(79)	(8)	22 (7)	247 (70)	17 (4)	77 (17)	(35)	4	93 (21)		29
TREAT NOW	440	53	(39)	(79)	(8)	33 (7)	347 (78)	17 (4)	//(1/)	(33)	4	93 (21)	cause	29
		(IQR											COVI	
Lopinavir/ritonavir-		18-	255	14	11	428	471	92		198			D-19	
TOGETHER ³²	471	94)	(54)	(3)	(2)	(91)	(100)	(20)	137 (29)	(42)	6	not reported	related	90
Tenofovir Disproxil														1
Fumarate Plus														
Emtricitabine-AR0-														1
CORONA ³³			34										all	
CORONA	60	12						2.	,		1			14
	60	42	(57)					2	3	1	4		cause	14

	1	1.0	l		l	1	1		1	ı	1	1	ı	1
Metformin-COVID-OUT ³⁴	119 7	46 (iqr 37- 55)	741 (56)	1091 (82)	90 (7)			26 (2)	353 (27) cvd	646 (49)	5	690 (52fv)	COVI D-19 related	28-30
		52	Ì											
Metformin -TOGETHER ³⁵		(18-	239			381	418	61		188			All	
	418	90)	(57)	8 (2)	6(1)	(91)	(100)	(15)	167 (40)	(45)	3		cause	28-30
	.10	, , ,	(0,)	S (=)	0 (1)	(>1)	(100)	(10)	10, (10)	(.0)	5		COVI	2000
Fluvoxamine-	149		862	1486		1486	1497	243		751			D-19	
TOGETHER ¹¹	7	<50	(58)	(99)	5 (1)	(99)	(100)	(16)	194 (13)	(50)	4	not reported	related	28-30
Fluvoxamine-STOP COVID ³⁶	152	46	109 (72)	106 (70)	38 (25)	5 (3)		17 (11)	30 (20)	75 (49)	4	not reported	COVI D-19 related	15 (2 noncov id after day 15 to day 28
		44											COVI	
Fluvoxamine-COVID- OUT ³⁴	502	(iqr37	358	539	51			7 (1)	172 (26)	302	_	272 (5(5)	D-19	20.20
00154	592	-53)	(54)	(82)	(8)			7(1)	cvd	(46)	5	373 (56fv)	related	28-30
	120	48		1000	0.6	221				4.60				
F1 : A COTTAL (27	128	(iqr39	734	1038	96	221		115	204 (24)	469	_	061 (67)	All	20
Fluvoxamine ACTIV-6 ³⁷	8	-58)	(57)	(81)	(7)	(17)		(9)	304 (24)	(36)	5	861 (67)	cause	28
		51												
Fluvoxamine/budesonide-	147	(18-	898	36	20	1419	1476	278		597			All	
TOGETHER ³⁸	6	102)	(61)	(2)	(1)	(96)	(100)	(19)	656 (44)	(42)	3	1377 (94)	cause	28-30
	134		791	1310	12	1310	1349	180		675			COVI D-19	
Ivermectin-TOGETHER ³⁹	9	49	(58)	(98)	(1)	(98)	(100)	(13)	114 (8)	(50)	4	not reported	related	28-30
		46							, ,			•	COVI	
i combonità	720	(iqr37	442	662	59			12 (2)	184 (23)	383	_	440 (565)	D-19	20.20
Ivermectin-COVID-OUT ³⁴	730	-56)	(55)	(82) 582	(7)			13 (2)	cvd	(47)	5	449 (56fv)	related	28-30
		35 (5-	294	(100				42		101			All	not
Ivermectin Iran ⁴⁰	549	87)	(48))	0	0	112 (20)	(7.3)	46 (7.8)	(21)	3	not reported	cause	stated
		47					. ,							
I A CITIV (41	159	(iqr39	932	1286	113(163		104	415	640		752 (6.47)	All	20.20
Ivermectin-ACTIV-6 ⁴¹	1	-56)	(59)	(81)	7)	(10)		184	415	648	6	753 (fv47)	cause	28-30
Ivermectin high dose-	100	48	712	000	02	1.00		100		250			A 11	
ACTIV-6 ⁴²	120	(iqr38	713	909	93	160		109	217 (27)	259	_	1000 (04)	All	20
	6	-58)	(59)	(75)	(8)	13)		(9)	317 (27)	(21)	5	1008 (84)	cause	28

		52	1	1		1	I	1	1	1	I	ı	ı	1
Hydroxychloroquine- TOGETHER ³²	441	53 (IQR 18- 81)	243 (55)	422 (96)	7(1)	422 (96)	441 (100)	89 (20)	210 (48)	177 (40)	6	not reported	COVI D-19 related	90
		40										•		
		(iqr												
Hydroxychloroquine-		32-	238	235	15								All	
COVID-19 PEP ⁴³	423	50)	(56)	(48)	(3)	28 (6)		15 (3)	46 (11)		2	not reported	cause	14
Hydroxychloroquine -AH COVID-19 ⁴⁴	1.40	47	66	<i>5</i> 1	10			20	41		7 (iqr5-	1	All	20.20
COVID-19**	148	47 42	(45)	51	12			29	41		8)	not reported	cause	28-30
Hydroxychloroquine-BCN		(12	201								3 (iqr 2-		All	
PEP-CoV-2 ⁴⁵	293	sd)	(69)				156 (53)	20 (7)			3 (iqi 2- 4)	not reported	cause	28-30
1B1 00 / 2	275	37	(0)				100 (00)	20 (1)			.,	посторогос	COVI	2000
Hydroxychloroquine-		(18-	131	117	26								D-19	
BMG^{46}	231	78)	(57)	(51)	(11)	71 (31)	129 (56)	17 (7)	27 (12)	98 (42)	6	not reported	related	28-30
Hydroxychloroquine-			176	165		158							all	
Utah ⁴⁷	303	42	(48)	(45)	2(1)	(43)	90 (25)	28 (8)	52 914)		nr	nr	cause	28
Hydroxychloroquine/Azithr			(-)	(-)		(-)	(-)	- (-)	,				all	
omycin-Brazil ⁴⁸	84	37	34	44	5	79		nr			4	25	cause	21
Omycm-Brazn	04	40	34	44	3	19		111	nr	nr	7	nr	COVI	21
		(12-	214	233		130	238						D-19	
Nitazoxanide-Romark ⁴⁹	379	83)	(57)	(61)	8 (2)	(34)	(63%)				2	38 (10)	related	28-30
		54										,		
		(iqr											COVI	
Colchicine-	448	47-	2421	4182	233		4488	894		2052			D-19	
COLCORONA ²	8	61)	(54)	(93)	(5)	<10%	(100)	(20)	1629 (36)	(46)	5.3	not reported	related	28-30
Losartan-MN ⁵⁰													all	
	117	38	58	84	8	10		7	9	42	2		cause	28
		36	26	53							not		All	
Niclosamide ⁵¹	67	mean	(39)	(79)	4 (6)	7 (10)			5 (8)	4 (7)	reported	not reported	cause	28-30
		54									10			
		(iqr	101	250	26			52		164	10		A 11	
Aspirin-ACTIV-4B ⁵²	280	46- 59)	191 (58)	250 (76)	36 (11)	93 (28)		53 (16)	109 (33)	164 (50)	(diagno sis)	not reported	All cause	45
Aspiriii-AC11V-4B	200	54	(36)	(70)	(11)	93 (26)		(10)	109 (33)	(30)	515)	not reported	cause	43
		(iqr									10			
2.5-mg apixaban-ACTIV-		46-	191	255	38			60		164	(diagno		All	
$4B^{52}$	271	59)	(58)	(78)	(12)	91 (28)		(18)	120 (37)	(50)	sis)	not reported	cause	45
											10			
5-mg apixaban ACTIV-	250	54	198	251	36	00 (2.0		55	111 (21)	164	(diagno		All	
$4B^{52}$	279	(iqr	(6	(77)	(11)	80 (24)		(17)	111 (34)	(50)	sis)	not reported	cause	45

	16							1					
			243										
		128	(100									All	
243		(53))		(100)		(21)	83 (43)		3	not reported	cause	21
	(iqr51	96	129				50/15	114/152	109			All	
219	-66)	(44)	(59)	5 (2)	12 (5)		2 (33)	(75)	(49)	5	not reported	cause	21
	56												
	(iqr53	217	446									All	
572	-62)	(38)	(78)	3(1)			38 (7)	115 (20)		3 (dx)	not reported	cause	28-30
	43									, ,	•		
		221	345	47	172				200			all	
400	`						30 (8)	89 (22)		NR			30
	, and the second	()		()	(10)		(0)	* (==)	(= =)				
		111										Δ11	
217	,		(100	0	0	157 (72)	33(16)	80 (41)	52 (24)	1	not reported		28-30
217	80)	(31)	,	U	U	137 (72)	33(10)	07 (41)	32 (24)	7	not reported		20-30
100	12	69	72	20			10	25	5.4				28
108	43	00	13	20			10	33	34	111	111		20
00	4.4	64	70	22			_	22	40				20
98	44	64	/0	23			3	22	49	nr	nr	+	28
100	4.6			22			•						•
108	46	62	71	32			20	41	54	nr	nr		28
												all	
86		56			(100)		8	21		9	nr	cause	27
	(24-	59	(100							not		All	
143	80)	(41))					33 (23)		reported	not reported	cause	23
		143	201	11								All	
292	46	(49)	(68)	(4)		70 (24)	25 (9)	52 (18)		6	not reported	cause	28-30
		130	169				24					All	
197	43	(66)	(86)	9 (5)	59 (30)		(12)	26 (13)		6	not reported	cause	21
	55	,		, ,	, ,			, ,			•		
		62	93				10					All	
100	84)	(59)	(89)	4 (4)	2 (2)	32 (30)	(10)		50 (50)	5	not reported	cause	21
	572 400 217 108 98 108 86 143 292 197	59 (iqr51 219 -66) 56 (iqr53 572 -62) 43 (13- 400 87) 63 (50- 217 86) 108 43 98 44 108 46 86 41 50 (24- 143 80) 292 46 197 43 55 (45-	59) 128 243 55 (53) 59 (iqr51) 96 219 -66) (44) 56 (iqr53) 217 572 -62) (38) 43 (13- 221 400 87) (55) 63 (50- 111 217 86) (51) 108 43 68 98 44 64 108 46 62 86 41 56 50 (24- 59 143 80) (41) 292 46 (49) 197 43 (66) 55 (45- 62	59) 243 243 128 (100 243 55 (53)) 59 (iqr51 96 129 219 -66) (44) (59) 56 (iqr53 217 446 572 -62) (38) (78) 43 (13- 221 345 400 87) (55) (86) 63 217 (100 217 86) (51)) 108 43 68 73 98 44 64 70 108 46 62 71 86 41 56 8 108 46 62 71 86 41 56 143 (24- 59 (100 143 80) (41)) 292 46 (49) (68) 197 43 (66) (86) 197 43 (66) (86) 193 (45- 62	59) 243 128 (100 59 (1qr51) 59 (1qr51) 56 (1qr53) 572 -66) 43 (13- 400 87) 63 217 (50- 111 108 43 68 73 28 98 44 64 70 23 108 46 62 71 32 86 41 56 - - 143 80) (41)) 143 201 11 292 46 (49) (68) (4) 197 43 (66) (86) 9 (5)	59)	243 59) L 243 (100 (100)) 243 (100) 244 (100) 244	59) I 243 (100 243 (100) 243 (100) 243 (100) 50 (21) 243 55 (53)) I I 243 (100) 243 (100) 50 (21) 59 (iqr51 96 (129 219) -66) (44) (59) 5(2) 12 (5) 2 (33) 50 (15 22) (38) (78) 3 (1) 12 (33) 12 (33) 572 -62) (38) (78) 3 (1) (13 221 345 47 172 400 87) (55) (86) (12) (43) 30 (8) 30 (8) 30 (8) 63 (50 111 (100) 217 86) (51)) 0 0 157 (72) 33(16) 30 (8) 108 43 68 73 28 100 100 100 157 (72) 33(16) 5 108 44 64 62 71 32 86 (100) 88 100 141 (100) 88 86 (100) 88 5 108 46 62 71 32 86 (100) 89 (100) 89 (141) 99 (100) 89 (100)	S9	S9	S9	S9	S90

Appendix Table 1b: Additional baseline data from RCTs-Geography, age symptom onset

Appendix Table 10. Additio	mai basciiii	c data 1	I OIII IXC I S	Geograf	my, age s	ympu	JIII UIIS	1	1	1	1
						age	age				
						over	over	symptoms	symptoms	symptoms	symptoms
	Enrollment	Study			age over	60	50	<= 8 days	<=7 days	<= 5 days	<= 3 days
Study	Period	months	Geography	Enrolled	65 n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
	Nov 10										
	2020 -July						376				
CCP-CONV-ert ⁷	28 2021	9	Spain	376			(100)		376 (100)		
							351				
CCP-COV-Early ¹³			Netherlands	406			(86)		406 (100)		
•	Aug 2020-						511				
CCP-C3PO ⁴	Feb 2021	7	USA	511			(100)		511 (100)		246 (48)
	Jun 4 2020								` ′		
	- Oct 25										
CCP-Argentina ⁵	2020	5	Argentina	160	160 (100)						160 (100)
	June 3										
	2020-Oct						410	1181			
CCP-CSSC-004 ³	2021	16	USA	1225	80 (7)		(35)	(100)		517 (44)	
	June 2020-									226	
Bamlanivimab-BLAZE-1 ¹⁴	Aug 2020	3	USA	467	53 (12)					(50)mean	
			United								
			States,								
	Aug 27		Canada,								
	2020-		Brazil, and							1057	
Sotrovimab-COMET-ICE ⁸	March 2021	6	Spain	1057	211(20)					(100)	624 (59)
Bamlanivimab/etesevimab-BLAZE-	Sept 2020-										
115	Dec 2020	3	USA	1035	323 (31)			979 (95)			
	Sept 24										
Casirivimab/imdevimab-REGEN-	2020-Jan 17		USA						2696		
COV Ph 3 ¹⁶	2021	4	Mexico	2696	358 (13)				(100)		1489 (66)
	June 16,										
Casirivimab/imdevimab-REGEN-	2020 - Sept										
COV Ph 1/2 ¹⁷	23, 2020	3	USA	799					799 (100)	599 (75)	400 (50)

	May 2021-									
Bebtelovimab-BLAZE-4 ¹	July 2021	3	USA	253	1 (<1)			253 (100)		
Bestelovillado BEARET	341y 2021	3	South	233	1 (1)			233 (100)		
			Korea,							
	Oct 2020-		Romania,			85				
Regdanvimab-CT-P59 ¹⁸	Dec 2020	2	Spain, USA	327		(26)		327 (100)		
rteguari inde er 133	Jan 18 2021		Spani, CST	327		(20)		327 (100)		
Regdanvimab-CT-P59-2 ¹⁹	to april 24						297			
	2021	3	world wide	1315			(23)		986 (75)	329 (25)
			USA, Latin				(==)		200 (12)	
	Jan 28,		America,							
Tixagevimab-cilgavimab-	2021- July		Europe, and							
TACKLE ²⁰	22, 2021,	6	Japan.	1014	116 (13)			910 (100)		
	May 2021-					246		, ,	1408	
Molnupiravir-MOVe-OUT ²¹	Oct 2021	6	worldwide	1433		(17)			(100)	674 (48)
	Dec 8-2021									
	- April 27,								22510	
Molnupiravir-PANORAMIC ²²	2022	5	UK	25783	6838 (27)				(87)	
	July 1, 2021									
	- Aug 24,									
Molnupiravir-Aurobindo ²³	2021	2	India	1220						661 (54)
	July 1 2021								2246	1489
Nirmatrelvir/ritonavir-EPIC-HR ⁹	- Dec 2021	6	worldwide	2246	287(12.8)				(100)	(66.3)
			USA,							
			Spain,							
	Sept 2020-		Denmark			170				
Remdesivir-PINETREE ¹²	Apr 2021	8	UK	562		(30)		562 (100)		
	Jun 24									
	2021-feb 7						752	1949		
Interferon Lambda-TOGETHER ²⁴	2022	8	Brazil	1949			(39)	(100)		1158 (59)
	May 18,									
	2020-Sep 4									
Interferon Lambda- ILIAD ²⁵	2020	4	Canada	60				60 (100)		

	Apil 25									
Interferon Lambda-COVID-	2020-July 7									
Lambda ²⁶	2020-3419 /	2	USA	120						
Lamoda-			USA	120						
	April 8									
Sofosbuvir and daclatasvir-	2020-May									
SOVODAK ²⁷	19 2020	1	Iran	55						
	July 23,					- 0				
	2020- Aug		Saudi			30				
Favipavir-Avi-Mild-19 ²⁸	4 2021	12	Arabia	245		(13)			231 (100)	
	Dec 5 2020-									
	mar 31									
Favipiravir-Iran ²⁹	2021	4	Iran	77				77 (100)		
	Oct 6 2020-		United							
Favipiravir-FLARE ³⁰	Nov 4 2021	13	Kingdom	119				119 (100)	76 (64)	
Favipiravir/Lopinavir/Ritonavir-	Oct 6 2020-		United							
FLARE ³⁰	Nov 4 2021	13	Kingdom	121				121 (100)	80 (66)	
	Oct 6 2020-		United							
Lopinavir/Ritonavir-FLARE ³⁰	Nov 4 2021	13	Kingdom	120				120 (100)	75 (63)	
	Jun 2020-					112				
Lopinavir/ritonavir-TREAT NOW ³¹	Dec 2021	18	USA	446	13 (3)	(25)		446 (100)	349 (78)	124 (28)
•	June 2									
	2020-Oct 9									
Lopinavir/ritonavir-TOGETHER ³²	2020	4	Brazil	471		275	471 (100)		74 (16)	
Tenofovir Disproxil Fumarate Plus	Nov 20						. ()		. (-)	
Emtricitabine-AR0-CORONA ³³	2020-Mar									
	19 2021	4	France	60				60 (100)	45 (75)	
	Dec 30	•	Trurice	00				00 (100)	13 (73)	
	2020 - Jan							1197		
Metformin-COVID-OUT ³⁴	28 2022	13	USA	1323				(100)		
Wicholiniii-CO v ID-OO I	jan 15	13	USA	1343				(100)		
Metformin -TOGETHER ³⁵	3					234				
Menorinii - TOGETHEK.	2021-April 13 2021	2	Brazil	418		(56)		418 (100)		184 (44)
		3	Drazii	418				` ′		184 (44)
TO CETATED!	Jan 2021 -		D "	1.407		655		1497		(20 (42)
Fluvoxamine-TOGETHER ¹¹	Aug 2021	8	Brazil	1497		(44)		(100)		638 (43)

	I			1	1		1	1	1	
	April 10									
	2020 - Aug									
Fluvoxamine-STOP COVID ³⁶	5 2020	4	USA	152				152 (100)	114 (75)	
	Dec 30							, ,	, ,	
	2020 - Jan									
Fluvoxamine-COVID-OUT ³⁴	28 2022	13	USA	661				733 (100)		
Fluvoxalililie-COVID-OUT	Au 6 2021-	13	USA	001				733 (100)		
25	May 27					541				
Fluvoxamine ACTIV-6 ³⁷	2022	10	USA	1288		(42)		966 (75)	644 (50)	
	Jan 15									
Fluvoxamine/budesonide-	2022-July 6					829		1476		
TOGETHER ³⁸	2022	6	Brazil	1476		(56)		(100)		917 (62)
	March 23 -							1358		
Ivermectin-TOGETHER ³⁹	Aug 2 2021	5	Brazil	1358				(100)		597 (44)
	Dec 30									
	2020 - Jan									
Ivermectin-COVID-OUT ³⁴	28 2022	13	USA	808				592 (100)		
Ivermeetiii-CO v ID-OC I		13	USA	808				392 (100)		
- 10	Feb 19 21 -	_								
Ivermectin Iran ⁴⁰	Aug 30 21	7	iran	582						291 (50)
	June 23									
	2021 - Feb					680				
Ivermectin-ACTIV-6 ⁴¹	4 2022	7	USA	1591		(43)	1193 (75)			
	feb 16									
Ivermectin high dose-ACTIV-6 ⁴²	2022-July									
	22 2022	5	USA	1206				905 (75)	603 (50)	302 (25)
	June 2		0011	1200				700 (70)	000 (00)	302 (20)
	2020-Oct 9					262				
Hydroxychlorogyina TOCETHED32	2020	4	Descrit	441		(59)	441 (100)		77 (17)	
Hydroxychloroquine-TOGETHER ³²		4	Brazil	441		(39)	441 (100)		77 (17)	
	March 22									
Hydroxychloroquine-COVID-19	2020 - May	_	USA			99				
PEP ⁴³	20 2020	2	canada	491		(20)			423 (100)	
	April 15									
Hydroxychloroquine -AH COVID-	2020 -May									
19 ⁴⁴	22 2020	1	Canada	148						

	March 17									
Hydroxychloroquine-BCN PEP-	2020-May									
CoV-2 ⁴⁵	26 2020	2	Spain	293					293 (100)	
C0V-2	April 15	2	Spain	273					273 (100)	
	2020-July					23				
Hydroxychloroquine-BMG ⁴⁶	27 2020	3	USA	231		(10)		143 (62)	85 (37)	
Trydroxycmoroqume-BWG	Apr 2020-	3	USA	231		(10)		143 (02)	03 (37)	
Hydroxychloroquine-Utah ⁴⁷	Apr 2020	12	USA	303						
11ydroxycmoroqume-otan	Apr 12	12	USA	303						
Hydroxychloroquine/Azithromycin-	2020-May									
Brazil ⁴⁸	13 2020	1	Brazil	83					84 (100)	
Diazii	Aug 2020-	1	USA Peurto	03					04 (100)	
Nitazoxanide-Romark ⁴⁹	Jan 2021	5	rico	379						379 (100)
Nitazoxamue-Romark	Jan 2021	3	Brazil,	319						379 (100)
			Canada,							
			Greece,							
			South							
	March		Africa,							
	2020-Dec		Spain, and			1122				
Colchicine-COLCORONA ²	2020-Dec 2020	9	the USA	4488		(25)	3590 (80)			
Losartan-MN ⁵⁰	Apr 2020-	9	the OSA	4400		(23)	3390 (80)			
Losartan-iviiv	Nov 2020	8	USA	117	3			117 (100)		106
	Oct 1 2020-	0	USA	11/	3			117 (100)		100
	April 20									
Niclosamide ⁵¹	2021	7	USA	73						67 (100)
Niciosamide	Sept 1 2020	/	USA	/3						67 (100)
	- June 17					~82				
Aspirin-ACTIV-4B ⁵²	2021	10	USA	328		(25)			82 (25)	
Aspitiii-AC11v-4D*-		10	USA	320		(23)			02 (23)	
	Sept 1 2020 - June 17					~82				
2.5-mg apixaban-ACTIV-4B ⁵²	2021	10	USA	329		(25)			82 (25)	
2.3-ing apixaoan-AC11V-4B	1	10	USA	329		(23)			02 (23)	
	Sept 1 2020 - June 17					~82				
5-mg apixaban ACTIV-4B ⁵²		10	USA	328					92 (25)	
3-mg apixaban ACTIV-4B ³²	2021	10	USA	328	<u> </u>	(25)			82 (25)	

	June 5 2020								
	- August 5								
Sulodexide ⁵³	2020	2	Mexico	243					243 (100)
Surodonide	2020		Belgium,	2.13					213 (100)
			Brazil,						
			India, South						
	Oct 27 2020		Africa,						
	- Nov 8		Spain, and			164			
Enoxaparin-ETHIC ⁵⁴	2021	12	the UK).	219		(75)		121 (50)	
•	Aug 5		Switzerland						
	2020-Jan 14		and			572		429 (dx	
Enoxaparin-OVID ⁵⁵	2022	17	Germany	572		(100)		75)	
•	jun 11								
Inhaled Ciclesonide-COVIS ⁵⁶	2020-nov 3								
	2020	5	USA	400					
	Dec 29								
	2020-July				151	217			
Inhaled ciclesonide-COVERAGE ⁵⁷	22 2021	7	France	217	(70)	(100)	217 (100)		
	Apr 27								
	2020-Oct								
Zinc ⁵⁸	14 2020	6	USA	108					
	Apr 27								
	2020-Oct								
Ascorbic acid ⁵⁸	14 2020	6	USA	98					
	Apr 27								
	2020-Oct								
Zinc/Ascorbic acid ⁵⁸	14 2020	6	USA	108					
	Jun 29								
	2020-Ap 6								
Homeopathy-COVID-Simile ⁵⁹	2021	10	Brazil	86					
	Dec 21								
	2020 -								
	March 1								
Saliravira ⁶⁰	2021	3	Iran	143					

Azithromycin-Atomic2 ⁶¹	June 3, 2020- Jan 29, 2021,	8	UK	292						
Azithromycin-ACTION ⁶²	May 22 2020 - March 16 2021	9	USA	197		18 (9)		197 (100)		
Resveratrol ⁶³	September 13, 2020 - December 11, 2020,	3	USA	100	16 (16)				50 (50)	

Appendix Table 2. Summary of findings table GRADE evaluation by RCT.

Patient or population: COVID-19 outpatients Settings: Ambulatory patients with COVID-19

Intervention: COVID-19 convalescent plasma, anti-Spike mAbs, small molecule antivirals and repurposed drugs

Comparison: standard of care, placebo

Study	Assumed risk-controls Illustrative comparativ	Correspondin g risk-Intervention Illustrative comparative	Effect size: OR (95% CI)	No of Participa nts (studies)	Quality of the evidence (GRADE)	Comments
ССР-	e risks* (95% CI) 120 per	risks* (95% CI)		2634	AAA A	CCP reduces
mITT all cause hospitaliz ation: cumulative results	120 per 1000	82 per 1000 (from 63 to 108)	0.69(0.53 /0.90)	participa nts (5 RCTs)	⊕⊕⊕⊕ high (there are no concerns in any of the GRADE factors)	significantly need of hospitalization compared to placebo. Most information is from results at low risk of bias or with some concerns, but unlikely to lower confidence in the estimate of effect.
Anti- spike mAbs: combined results	58.9 per 1000	18.8 per 1000 (from 14.7to 22.1)	0.32(0.25 /0.41)	8736 (9 trials)	⊕⊕⊕⊝ moderate (downgraded for ROB)	Anti-Spike mAbs reduce hospitalization compared to placebo
Small molecule antivirals	18.3 per 1000	14.3 per 1000 (from 8.2 to 24.3)	0.78(0.45 /1.33)	34104 (17)	⊕⊖⊖ very-low (downgraded for imprecision,	-It is unclear if antivirals reduce rate of hospitalization compared to placebo

combined results Repurpos ed drugs combined results	53.05 per 1000	41.9 per 1000 (from 37.1 to 47.7)	0.79(0.70 /0.90)	22512 (39 arms, 21 comparis ons)	inconsistency $(I^2=69)$ and ROB) $\bigoplus \bigoplus \bigoplus \bigoplus$ moderate (downgraded for ROB)	Repurposed treatments reduce rate of hospitalization compared to placebo			
CCP	CCP								
CCP- CONV-ert ⁷	111 per	116 per 1000 (from 61 to 219)	1.05 (0.55/1.9 8)	376 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	CCP does not reduce hospitalization compared to placebo			
CCP-COV- Early ¹³	93 per 1000	3 per 1000 (from 26.9 to (0.29/1.3 406 (1) moder for im		⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if CCP reduces hospitalization compared to placebo				
CCP-C3PO ⁴	220 per 1000	198 per 1000 (from 127 to 301)	0.9 (0.58/1.3 7)	511 (1)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if CCP reduces hospitalization compared to placebo			
CCP- Argentina ⁵	312 per	133 per 1000 (from 62 to 180)	0.43 (0.20/0.9 1)	160 (1)	⊕⊕⊕⊝ moderate (downgraded for imprecision due to low number of participants)	CCP reduces rate of hospitalization compared to placebo			
CCP-CSSC-004 ³	62.8 per 1000	27.6 per 1000 (from 15.7 to 49.6)	0.44 (0.25/0.7 9)	1181 (1)	⊕⊕⊕⊕ high (there are no concerns in any of the GRADE factors)	CCP reduces rate of hospitalization compared to placebo			
Anti-Spike n			T	T					
Bamlanivi mab ¹⁴	62.9 per 1000	15 per 1000 (from 5 to 46.5)	0.24 (0.08/0.7 4)	919 (1 RCT)	⊕⊕⊕⊖ moderate (downgraded for imprecision)	Bamlanivimab reduces need of hospitalization compared to placebo			

Sotrovima b- COMET- ICE ²³	56.7 1000	per	10.7 per 1000 (from 4.5 to 26)	0.19 (0.08/0.4 6)	1061 (1 RCT)	⊕⊕⊕⊝ moderate (downgraded for ROB)	Sotrovimab reduces need of hospitalization compared to placebo
Bamlanivi mab/etese vimab ¹⁵	69.3 1000	per	20 per 1000 (from 10.3 to 40.1)	0.29 (0.15/0.5 8)	1035 (1 RCT)	⊕⊕⊖⊝ low(downgraded for imprecision and ROB)	Bamlanivimab/etesevi mab in combination reduce need of hospitalization compared to placebo
Casirivim ab/imdevi mab ¹⁶	41.6 1000	per	11.6 per 1000 (from 7.0 to 19.1)	0.28 (0.17/0.4 6)	3495 (2 RCT)	⊕⊕⊖⊖ low (downgraded for ROB and imprecision due to low number of events)	Casirivimab/imdevima b in combination reduce need of hospitalization compared to placebo
Bebtelovi mab- BLAZE- 41	15.6 1000	per	15.9 per 1000 (from 2.1 to 115)	1.02 (0.14/7.3 9)	253 (1 RCT)	⊕⊕⊖ low (downgraded twice for serious imprecision)	Bebtelovimab does not reduce need of hospitalization compared to placebo
Regdanvi mab ^{18,19}	79.9 1000	per	26.3 per 1000 (from 5.9 to 42.3)	0.33 (0.20/0.5 3)	1622 (2 RCTs)	⊕⊕⊕⊝ moderate (downgraded for ROB)	Regdanviman reduces hospitalization compared to placebo
Tixagevi mab— cilgavima b- TACKLE ²	89.1 1000	per	41.8 per 1000 (from 24 to 74.7)	0.47 (0.27/0.8 4)	822 (1)	⊕⊕⊕⊝ moderate (downgraded for imprecision)	Tixagevimab- cilgavimab reduces hospitalization compared to placebo in unvaccinated adults
Small molec		rals					
Molnupira vir ²¹⁻²³	11.8 1000	per	10.8 per 1000 (from 8.6 to 13.4)	0.91 (0.73/1.1 4)	27628 (3 RCTs)	⊕⊕⊖⊖ low(downgraded for inconsistency and imprecision)	It is unclear if Molnupiravir reduces hospitalization compared to placebo
Nirmatrel vir/ritonav ir ⁹	63 per 10	000	7.5 per 1000 (from 3.7 to 15.1)	0.12 (0.06/0.2 4)	2085 (1)	⊕⊕⊖ low (downgraded for ROB and imprecision).	Nirmatrelvir/ritonavir reduces hospitalization

						compared to placebo in unvaccinated adults
Remdesivi r ¹²	53 per 1000	6.8 per 1000 (from 1.5 to 50.2)	0.13 (0.03/0.5 7)	562 (1)	⊕⊕⊖⊝ low (downgraded for ROB and imprecision)	Remdesivir reduces hospitalization compared to placebo
Favipiravi r ²⁸⁻³⁰	18.3 per 1000	51.2 per 1000 (from 16.8 to 155.9)	2.80 (0.92/18. 52)	427 (3)	⊕⊕⊖ low (downgraded for serious imprecision)	Favipiravir does not reduce need of hospitalization compared to placebo
Favipiravi r- Lopinavir/ r- FLARE ³⁰	Not calculable	1	3.05 (0.12/76. 39)	120 (1)	⊕⊕⊖ low (downgraded for serious imprecision)	Favipiravir+Lopinavir/r does not reduce need of hospitalization compared to placebo
Peg- interferon lambda ²⁴⁻	38.8 per 1000	23.2 per 1000 (from 13.9 to 38.4)	0.60 (0.36/0.9 9)	2129 (3 RCTs)	⊕⊕⊕⊝ moderate (downgraded for ROB)	-Peginterferon lambda reduces hospitalization compared to placebo.
Sofosbuvi r and daclatasvi r- SOVODA K ²⁷	142.8 per 1000	32.8 per 1000 (from 2.8 to 315)	0.23 (0.02/2.2 1)	55 (1)	⊕⊕⊖⊝ low (downgraded for serious imprecision)	It is unclear if sofosbuvir/daclatasvir reduces hospitalization compared to placebo
Lopinavir/ ritonavir ³⁰	33.1 per 1000	41.4 per 1000 (from 21.8 to 78.4)	1.25 (0.66/2.3 7)	1037 (3)	⊕⊕⊖⊖ low (downgraded for serious imprecision)	Lopinavir/ritonavir does not reduce need of hospitalization compared to placebo
Tenofovir Disproxil Fumarate Plus Emtricitabi ne-AR0- CORONA	33.3 per 1000	68.9 per 1000 (from 5.9 to 804.1	2.07 (0.18/24. 5)	60 (1 RCT)	⊕⊖⊖⊖ very-low (downgraded for serious imprecision and ROB)	TDF+Emtricitabine does not reduce need of hospitalization compared to standard of care

Repurposea	!						
Metformi n- COVID- OUT ^{34,35}	53.4	per	37.4 per 1000 (from 22.9 to 60.3)	0.70 (0.43/1.1 3	1615 (2 RCTs)	$\bigoplus \bigoplus \bigoplus$ low (downgraded for imprecision and inconsistency (I^2 =58)	It is unclear if metformin reduces hospitalization compared to placebo.
Fluvoxam ine ^{11,34,36,37}	63.6 1000	per	46.4 per 1000 (from 34.3 to 62.9)	0.73 (0.54/0.9 9)	3518 (4 RCTs)	⊕⊕⊕⊝ moderate (downgraded for ROB)	Fluvoxamine reduces hospitalization compared to placebo
Fluvoxami ne/budeson ide- TOGETHE R ³⁸	10.8	per	9.4 per 1000 (from 3.4 to 26.1)	0.87 (0.32/2.4 2)	1476 (1 RCT)	⊕⊕⊕⊝ moderate (downgraded imprecision)	It is unclear if fluvoxamine/budenosid e reduces hospitalization compared to placebo.
Ivermecti n ^{10,34,40-42}	46.3 1000	per	43.1 per 1000 (from 32.8 to 56.0)	0.93 (0.71/1.2 21	5434 (5 RCTs)	⊕⊕⊕⊜ moderate (downgraded imprecision)	-It is unclear if Ivermectin reduces rate of hospitalization compared to placebo
Hydroxyc hloroquin e ^{32,43,64-66}	44.0per 1000		38.7 per 1000 (from 22.8 to 65.1)	0.74 (0.45/1.2 3)	1536 (6 RCTs)	⊕⊕⊕⊖ moderate (downgraded for imprecision-95% CI includes line of no effect)	It is unclear if hydroxychloroquine reduces hospitalization compared to placebo
Hydroxych loroquine/a zithromyci n ⁴⁸	23.8 1000	per	23.8 per 1000 (from 1.42 to 39.2)	1.00 (0.06/16. 5)	84 (1 RCT)	⊕⊕⊖⊝ low (downgraded for imprecision and ROB)	It is unclear if hydroxychloroquine/azi thromycin reduces hospitalization compared to placebo
Nitazoxan ide- Romark ⁴⁹	1000	per	5.3 per 1000 (from 0.5 to 45.8)	0.21 (0.02/1.7 9)	379 (1)	⊕⊖⊖ very-low (downgraded for serious imprecision and ROB)	It is unclear if nitazoxanide reduces hospitalization compared to placebo
Colchicin e-	58.1 1000	per	45.8 per 1000 (from 35.4 to 59.8)	0.79 (0.61/1.0 3)	379 (1)	⊕⊕⊕⊖ moderate (downgraded	It is unclear if colchicine reduces

hospitalization
compared to placebo
It is unclear if losartan
reduces rate of
hospitalization
compared to placebo
It is unclear if
niclosamide reduces
hospitalization
compared to placebo
Aspirin does not reduce
need of hospitalization
compared to placebo
Apibaxan 2.5-5 mg
does not reduce need of
hospitalization
compared to placebo
Sulodexide reduces
hospitalization
compared to placebo
LMW heparin does not
reduce hospitalization
•
compared to placebo
Inhaled ciclesonide
does not reduce need of
hospitalization
compared to placebo
Zinc, ascorbic acid and
combination of both did
not reduce rate of
hospitalization compared
with usual care.

Zinc/Ascor bic acid ⁵⁸	60 per 1000	129 per 1000 (from 31.8 to 528)	2.15 (0.53/8.8 0)	108 (1 RCT)	⊕⊖⊖⊖ very-low (downgraded for serious imprecision and ROB)	
Homeopath y-COVID- Simile ⁵⁹	68.1 per 1000	22.5 per 1000 (from 2.0 to 227.4)	0.33 (0.03/3.3 4)	86 (1 RCT)	⊕⊖⊖ very-low (downgraded for imprecision and serious ROB)	It is unclear if homeopathy reduces hospitalization compared to placebo
Saliravira ⁶	285 per 1000	133.9 per 1000 (from 82.6 to 220.2)	0.47 (0.29/0.7 7)	143 (1)	⊕⊖⊖ very-low (downgraded for serious imprecision and serious ROB)	Saliravira reduces hospitalization compared to control
Azithrom ycin ^{61,62}	77.6 per 1000	85.3 per 1000 (from 43.4 to 169.1)	1.10 (0.56/2.1 8)	489 (2)	⊕⊕⊖⊝ low (downgraded for serious imprecision)	azithromycin does not reduce hospitalization compared to placebo
Resveratr ol ⁶³	60 per 1000	19.2 per 1000 (from 1.8 to 190.8)	0.32 (0.03/3.1 8)	100 (1)	⊕⊕⊖⊝ low (downgraded for serious imprecision)	It is unclear if resveratrol reduces hospitalization compared to placebo

^{*}The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect (the Risk Difference, also called ARR, absolute risk reduction) of the intervention (and its 95% CI).

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

Footnote: OR, Odds Ratio; CIs, confidence intervals; ROB, risk of bias. GRADE, Grading of Recommendations, Assessment, Development and Evaluations

Appendix Table 3: Hospitalized Odds Ratio statistics

Appendix Table 3: Hospita Study	Hospitaliza tion Odds ratio	Hospitaliza tion 95 CI low	Hospitaliza tion 95 CI high	Hospitaliza tion significance (p)	Hospitaliza tion z statistic
Total CCP	0.69	0.53	0.90	0.0035	2.697265
Total mAb	0.31	0.24	0.4	P<0.001	9.29792
Total antivirals	0.78	0.45	1.33	P<0.001	3.9493
Total repurposed	0.82	0.72	0.93	P<0.001	3.74264
Total	0.67	0.57	0.80	P<0.001	9.01288
CCP-CONV-ert ⁷	1.05	0.56	1.99	0.4356	0.162033
CCP-COV-Early ¹³	0.61	0.29	1.30	0.1021	1.269694
CCP-C3PO ⁴	0.90	0.59	1.37	0.3078	0.502004
CCP-Argentina ⁵	0.43	0.20	0.91	0.0140	2.197789
CCP-CSSC-004 ³	0.44	0.25	0.79	0.0031	2.737543
CCP-Argentina (high titer) ⁵	0.20	0.06	0.71	0.0132	2.478
CCP-CSSC-004 (<= 5 days)	0.18	0.07	0.49	0.0007	3.38
Bamlanivimab-BLAZE-1 ¹⁴	0.24	0.08	0.74	0.0066	2.479993
Sotrovimab-COMET-ICE ⁸	0.19	0.08	0.46	0.0001	3.663844
Bamlanivimab/etesevimab-BLAZE-1 ¹⁵	0.29	0.15	0.58	0.0002	3.534471
Casirivimab/imdevimab- REGEN-COV Ph 3 ¹⁶	0.28	0.16	0.47	0.0000	4.734662
Casirivimab/imdevimab- REGEN-COV Ph 1/2 ¹⁷	0.30	0.07	1.25	0.0484	1.660556
Bebtelovimab-BLAZE-4 ¹	1.02	0.14	7.39	0.4905	0.023906
Regdanvimab-CT-P59 ¹⁸	0.49	0.19	1.27	0.0716	1.463817
Regdanvimab-CT-P59-2 ¹⁹	0.29	0.16	0.52	0.00001	4.22581
Tixagevimab–cilgavimab– TACKLE ²⁰	0.47	0.26	0.84	0.0057	2.528551
Molnupiravir-MOVe-OUT ²¹	0.67	0.46	0.99	0.0223	2.00829
Molnupiravir- PANORAMIC ²²	1.07	0.81	1.42	0.3156	0.479984
Molnupiravir-Aurobindo ²³	NA	NA	NA	NA	NA
Nirmatrelvir/ritonavir- EPIC-HR ⁹	0.12	0.06	0.24	0.0000	5.731691
Remdesivir-PINETREE ¹²	0.13	0.03	0.57	0.0034	2.703067
Interferon Lambda- TOGETHER ²⁴	0.47	0.29	0.77	0.0011	3.054966
Interferon Lambda- ILIAD ²⁵	1.00	0.06	16.76	0.5000	0
Interferon Lambda-COVID- Lambda ²⁶	1.00	0.14	7.34	0.5000	0
Sofosbuvir and daclatasvir- SOVODAK ²⁷	0.23	0.02	2.21	0.1018	1.271414

Favipavir-Avi-Mild-19 ²⁸	3.31	0.65	16.76	0.0739	1.44706
Favipiravir-Iran ²⁹	2.18	0.37	12.65	0.19324	0.86602
Favipiravir-FLARE ³⁰	3.1	0.12	77.71	0.24541	0.68902
Favipiravir/Lopinavir/Riton avir-FLARE ³⁰	3	0.12	75.11	0.25187	0.66863
Lopinavir/Ritonavir- FLARE ³⁰	3.05	0.12	76.39	0.24865	0.67874
Lopinavir/ritonavir-TREAT NOW ³¹	1.21	0.4	3.64	0.37059	0.3303
Lopinavir/ritonavir- TOGETHER ³²	1.20	0.53	2.69	0.3333	0.430926
Tenofovir Disproxil Fumarate Plus Emtricitabine-AR0- CORONA ³³					
24	2.07	0.18	24.15	0.28057	0.58116
Metformin-COVID-OUT ³⁴	0.42	0.18	0.96	0.0198	2.057
Metformin -TOGETHER ³⁵	0.94	0.51	1.71	0.41626	0.21147
Fluvoxamine- TOGETHER ¹¹	0.77	0.56	1.05	0.0505	1.640023
Fluvoxamine-STOP COVID ³⁶	0.06	0.00	1.15	0.0310	1.866043
Fluvoxamine-COVID-					
OUT ³⁴	1.18	0.36	3.91	0.3935	0.270145
Fluvoxamine ACTIV-6 ³⁷	0.45	0.04	5	0.25869	0.64738
Fluvoxamine/budesonide- TOGETHER ³⁸	0.87	0.32	2.42	0.39769	0.25933
Ivermectin-TOGETHER ³⁹	0.81	0.59	1.11	0.09724	1.29742
Ivermectin-COVID-OUT ³⁴	0.76	0.20	2.85	0.3414	0.408715
Ivermectin Iran ⁴⁰	1.46	0.71	2.96	0.1507	1.033341
Ivermectin-ACTIV-6 ⁴¹	1.05	0.43	2.61	0.4553	0.112309
Ivermectin high dose-ACTIV-6 ⁴²					
	2.52	0.49	13.04	0.13512	1.10252
Hydroxychloroquine-					
TOGETHER ³²	0.76	0.30	1.93	0.2840	0.570928
Hydroxychloroquine- COVID-19 PEP ⁴³	0.49	0.16	1.45	0.0971	1.298164
Hydroxychloroquine -AH					
COVID-19 ⁴⁴	3.14	0.17	59.70	0.2232	0.761332
Hydroxychloroquine-BCN PEP-CoV-2 ⁴⁵	0.83	0.32	2.13	0.3486	0.389184
Hydroxychloroquine-	0.03	0.32	2.13	0.5700	0.307107
BMG ⁴⁶	0.69	0.18	2.65	0.2945	0.54027
Hydroxychloroquine-Utah ⁴⁷	1.77	0.51	6.19	0.18429	0.89915
Hydroxychloroquine/Azithr omycin-Brazil ⁴⁸	1	0.06	16.5	0.5	0

Nitazoxanide-Romark ⁴⁹	0.21	0.02	1.79	0.0766	1.428571
Colchicine-COLCORONA ²	0.79	0.61	1.03	0.0407	1.742726
Losartan-MN ⁵⁰	0.112			010101	
	3.16	0.32	31.34	0.16245	0.98443
Niclosamide ⁵¹	0.33	0.01	8.48	0.2529	0.665353
Aspirin-ACTIV-4B ⁵²	0.94	0.06	15.24	0.4838	0.040562
2.5-mg apixaban-ACTIV-					
$4B^{52}$	1.01	0.06	16.27	0.4979	0.005238
5-mg apixaban ACTIV-4B ⁵²	1.91	0.17	21.36	0.2988	0.527902
Sulodexide ⁵³	0.52	0.28	0.95	0.0167	2.128119
Enoxaparin-ETHIC ⁵⁴	1.10	0.47	2.56	0.4155	0.213485
Enoxaparin-OVID ⁵⁵	1.02	0.38	2.76	0.4862	0.034489
Inhaled Ciclesonide-					
COVIS ⁵⁶					
	0.48	0.12	1.87	0.14459	1.05994
Inhaled ciclesonide-					
COVERAGE ⁵⁷	1.15	0.51	2.63	0.3659	0.34277
Zinc ⁵⁸	1.48	0.36	6.52	0.30296	0.5159
Ascorbic acid ⁵⁸	0.68	0.11	4.27	0.34085	0.41015
Zinc/Ascorbic acid ⁵⁸	2.15	0.53	8.8	0.1435	1.06472
Homeopathy-COVID-	0.33	0.03	3.34	0.17503	0.93449
Simile ⁵⁹	0.55	0.03	3.34	0.17303	0.93449
Saliravira ⁶⁰	0.01	0.00	0.24	0.0016	2.9467
Azithromycin-Atomic2 ⁶¹	0.88	0.42	1.84	0.3694	0.333472
Azithromycin-ACTION ⁶²	6.62	0.36	121.45	0.1015	1.272994
Resveratrol ⁶³	0.32	0.03	3.18	0.1654	0.972432

Appendix Table 4: Deaths during RCTs

Cumulatively, the CCP RCTs noted 10 deaths in the control arm versus 8 in CCP arm. The anti-Spike mAbs RCTs had 21 total deaths among controls and 4 in the intervention arm. The total for all small molecule antiviral RCTs was 28 in the controls and 7 in the interventions. The repurposed drugs RCTs recorded 72 deaths in the control groups and 53 in the intervention

groups. Od 95% 95% ds 95 \mathbf{Z} RRR CI 95 CI ARR CI CI rati statis signific Study % % **ARR RRR** 0 low high tic ance (p) (-(-0.48,0.478 2.02 0.15 20.2 101.5, 0.8 0.31 0.31616 0.78) 48 Total CCP 68.4) (0.21,(49.4,0.1 3.345 0.00041 0.45 80.8 0.07 0.5 9 9 Total mAb 0.7)92.7) (0.1,(63.4,0.1 3.851 87.1 0.05 0.00006 0.16 0.37 Total antivirals 0.23) 95.4) 3 81 (-0.1,(-8.3,0.7 1.479 0.0695 0.16 21.8 0.56 1.08 8 5 Total repurposed 0.4)43.5) (27.6,0.5 4.299 (0.11,0.19 44.7 0.42 0.72 0.00001 0.28) 57.8) 5 06 Total Tot **%** al **Deat** Tota Death deat % bot **Total** h death hs h interv interv cont interv cont cont ar Study rol rol ent. ent. rol ent. ms 263 10 1315 8 1319 0.76 0.61 **Total CCP** 4 873 23 4102 5 4634 0.56 0.11 Total mAb 6 1707 341 4 31 17031 0.18 0.02 **Total antivirals** 3 04 1110 225 81 65 11396 0.73 0.57 05 **Total repurposed** 2968 600 0.24 **Total** 131 0 72 30363 43 0.44 CCP-CONV-ert⁷ 2 188 0 188 376 1.06 0 0 204 CCP-COV-Early¹³ 1 202 406 0 0.5 5 CCP-C3PO⁴ 1 254 257 511 0.39 1.95 4 2 5 2.5 80 80 160 CCP-Argentina⁵ 118 3 589 0 592 0.51 0 CCP-CSSC-004³ 452 Bamlanivimab-BLAZE-1¹⁴ 0 143 0 309 0 0 105 2 529 0 528 0.38 0 7 Sotrovimab-COMET-ICE⁸ 103 Bamlanivimab/etesevimab-10 517 0 1.93 0 518 BLAZE-115

Casirivimab/ imdevimab-REGEN- COV Ph 3 ¹⁶	3	1341	1	1355	269 6	0.22	0.07	
Casirivimab/ imdevimab-REGEN- COV Ph 1/2 ¹⁷	0	266	0	533	799	0	0	
Bebtelovimab-BLAZE-	0	128	0	125	253	0	0	
Regdanvimab-CT-P59 ¹⁸	0	104	0	203	307	0	0	
Regdanvimab-CT-P59- 2 ¹⁹	2	659	1	656	131 5	0.3	0.15	
Tixagevimab— cilgavimab-TACKLE ²⁰	6	415	3	407	822	1.45	0.74	
Molnupiravir-MOVe- OUT ²¹	9	699	1	709	140 8	1.29	0.14	
Molnupiravir- PANORAMIC ²²	5	1248 4	2	12516	250 00	0.04	0.02	
Molnupiravir- Aurobindo ²³	0	610	0	610	122 0	0	0	
Nirmatrelvir/ritonavir- EPIC-HR ⁹	12	1046	0	1039	208 5	1.15	0	
Remdesivir- PINETREE ¹²	1	283	0	279	562	0.35	0	
Interferon Lambda- TOGETHER ²⁴	4	1018	1	931	194 9	0.4	0.11	
Interferon Lambda- ILIAD ²⁵	0	30	0	30	60	0	0	
Interferon Lambda- COVID-Lambda ²⁶	0	60	0	60	120	0	0	
Sofosbuvir and daclatasvir-SOVODAK ²⁷	0	28	0	27	55	0	0	
Favipavir-Avi-Mild-19 ²⁸	0	119	0	112	231	0	0	
Favipiravir-Iran ²⁹	0	39	0	38	77	0	0	
Favipiravir-FLARE ³⁰	0	60	0	59	119	0	0	
Favipiravir/Lopinavir/Ri tonavir-FLARE ³⁰	0	60	0	61	121	0	0	
Lopinavir/Ritonavir- FLARE ³⁰	0	60	0	60	120	0	0	
Lopinavir/ritonavir- TREAT NOW ³¹	0	220	0	226	446	0	0	
Lopinavir/ritonavir- TOGETHER ³²	0	227	0	244	471	0	0	
Tenofovir Disproxil Fumarate Plus Emtricitabine-AR0- CORONA ³³	0	30	0	30	60	0	0	

Metformin-COVID- OUT ³⁴	1	601	1	596	119 7	0.17	0.17	
Metformin - TOGETHER ³⁵	9	203	7	215	418	4.4	3.2	
Fluvoxamine- TOGETHER ¹¹	25	756	17	741	149 7	3.31	2.29	
Fluvoxamine-STOP COVID ³⁶	0	72	0	80	152	0	0	
Fluvoxamine-COVID- OUT ³⁴	0	293	0	299	592	0	0	
Fluvoxamine ACTIV-6 ³⁷	0	599	0	662	126 1	0	0	
Fluvoxamine/budesonid e-TOGETHER ³⁸	0	738	1	738	147 6	0	0.14	
Ivermectin- TOGETHER ³⁹	24	675	21	674	134 9	3.56	3.12	
Ivermectin-COVID- OUT ³⁴	0	356	1	374	730	0	0.27	
Ivermectin Iran ⁴⁰	1	281	1	268	549	0.36	0.37	
Ivermectin-ACTIV-6 ⁴¹	0	774	1	817	159 1	0	0.12	
Ivermectin high dose-ACTIV-6 ⁴²	0	604	1	602	120 6	0	0.17	
Hydroxychloroquine- TOGETHER ³²	1	227	0	214	441	0.44	0	
Hydroxychloroquine- COVID-19 PEP ⁴³	1	211	1	212	423	0.47	0.47	
Hydroxychloroquine - AH COVID-19 ⁴⁴	0	37	0	111	148	0	0	
Hydroxychloroquine- BCN PEP-CoV-2 ⁴⁵	0	157	0	136	293	0	0	
Hydroxychloroquine- BMG ⁴⁶	0	83	0	148	231	0	0	
Hydroxychloroquine- Utah ⁴⁷	0	151	0	152	303	0	0	
Hydroxychloroquine/Azi thromycin-Brazil ⁴⁸	0	42	0	42	84	0	0	
Nitazoxanide-Romark ⁴⁹	0	195	0	184	379	0	0	
Colchicine- COLCORONA ²	9	2253	5	2235	448 8	0.4	0.22	
Losartan-MN ⁵⁰	0	59	0	58	117	0	0	
Niclosamide ⁵¹	0	34	0	33	67	0	0	
Aspirin-ACTIV-4B ⁵²	0	136	0	144	280	0	0	

2.5-mg apixaban- ACTIV-4B ⁵²	0	136	0	135	271	0	0	
5-mg apixaban ACTIV- 4B ⁵²	0	136	0	143	279	0	0	
Sulodexide ⁵³	7	119	3	124	243	5.88	2.42	
Enoxaparin-ETHIC ⁵⁴	0	114	1	105	219	0	0.95	
Enoxaparin-OVID ⁵⁵	0	238	0	234	472	0	0	
Inhaled Ciclesonide-COVIS ⁵⁶	0	203	0	197	400	0	0	
Inhaled ciclesonide- COVERAGE ⁵⁷	2	107	0	110	217	1.87	0	
Zinc ⁵⁸	0	50	0	58	108	0	0	
Ascorbic acid ⁵⁸	0	50	1	48	98	0	2.08	
Zinc/Ascorbic acid ⁵⁸	0	50	2	58	108	0	3.45	
Homeopathy-COVID- Simile ⁵⁹	0	44	0	42	86	0	0	
Saliravira ⁶⁰	0	56	0	87	143	0	0	i
Azithromycin-Atomic2 ⁶¹	1	147	1	145	292	0.68	0.69	· ·
Azithromycin- ACTION ⁶²	0	72	0	125	197	0	0	
Resveratrol ⁶³	0	50	0	50	100	0	0	

Appendix References

- 1. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. *medRxiv* 2022: 2022.03.10.22272100.
- 2. Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebocontrolled, multicentre trial. *Lancet Respir Med* 2021; **9**(8): 924-32.
- 3. Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med* 2022.
- 4. Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. *N Engl J Med* 2021; **385**(21): 1951-60.
- 5. Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021; **384**(7): 610-8.
- 6. Millat-Martinez P, Gharbharan A, Alemany A, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. *Nature Communications* 2022; **13**(1): 2583.
- 7. Alemany A, Millat-Martinez P, Corbacho-Monne M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. *Lancet Respir Med* 2022; **10**(3): 278-88.
- 8. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. *N Engl J Med* 2021.
- 9. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med* 2022; **386**(15): 1397-408.
- 10. Reis G, Silva E, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. *N Engl J Med* 2022.
- 11. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health* 2022; **10**(1): e42-e51.
- 12. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *N Engl J Med* 2022; **386**(4): 305-15.
- 13. Gharbharan A, Jordans C, Zwaginga L, et al. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial. *Clin Microbiol Infect* 2022.
- 14. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med* 2021; **384**(3): 229-37.
- 15. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. *N Engl J Med* 2021; **385**(15): 1382-92.
- 16. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med* 2021; **385**(23): e81.
- 17. Norton T, Ali S, Sivapalasingam S, et al. REGEN-COV Antibody Combination in Outpatients With COVID-19 Phase 1/2 Results. *medRxiv* 2022: 2021.06.09.21257915.
- 18. Streinu-Cercel A, Sandulescu O, Preotescu LL, et al. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* 2022; **9**(4): ofac053.

- 19. Kim JY, Sandulescu O, Preotescu LL, et al. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. *Open Forum Infect Dis* 2022; **9**(8): ofac406.
- 20. Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Respir Med* 2022; **10**(10): 985-96.
- 21. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2022; **386**(6): 509-20.
- 22. Butler C, Hobbs FDR, Gbinigie O, et al. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial. *SSRN* 2022; **ssrn.4237902**.
- 23. Tippabhotla SK, Lahiri S, Rama Raju D, Kandi C, Prasad VN. Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial. . *SSRN* 2022; **4042673**.
- 24. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. *N Engl J Med* 2023; **388**(6): 518-28.
- 25. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *Lancet Respir Med* 2021; **9**(5): 498-510.
- 26. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nature Communications* 2021; **12**(1): 1967.
- 27. Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *Journal of Antimicrobial Chemotherapy* 2020; **76**(3): 753-7.
- 28. Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. *Clin Microbiol Infect* 2022; **28**(4): 602-8.
- 29. Vaezi A, Salmasi M, Soltaninejad F, Salahi M, Javanmard SH, Amra B. Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. *Adv Respir Med* 2023; **91**(1): 18-25.
- 30. Lowe DM, Brown LK, Chowdhury K, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. *PLoS Med* 2022; **19**(10): e1004120.
- 31. Kaizer AM, Shapiro NI, Wild J, et al. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. *Int J Infect Dis* 2023; **128**: 223-9.
- 32. Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**(4): e216468.
- 33. Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. *EClinicalMedicine* 2021; **38**: 100993.

- 34. Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. *N Engl J Med* 2022; **387**(7): 599-610.
- 35. Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. *Lancet Reg Health Am* 2022; **6**: 100142.
- 36. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA* 2020; **324**(22): 2292-300.
- 37. McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2023; **329**(4): 296-305.
- 38. Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial. *Ann Intern Med* 2023; **176**(5): 667-75.
- 39. Reis G, Silva E, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. *N Engl J Med* 2022; **386**(18): 1721-31.
- 40. Rezai MS, Ahangarkani F, Hill A, et al. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. *Front Med (Lausanne)* 2022; **9**: 919708.
- 41. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2022; **328**(16): 1595-603.
- 42. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. *JAMA* 2023; **329**(11): 888-97.
- 43. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. *Ann Intern Med* 2020; **173**(8): 623-31.
- 44. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *CMAJ Open* 2021; **9**(2): E693-E702.
- 45. Mitja O, Reis G, Boulware DR, et al. Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. *Clin Transl Sci* 2023; **16**(3): 524-35.
- 46. Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *EClinicalMedicine* 2021; **33**: 100773.
- 47. Spivak AM, Barney BJ, Greene T, et al. A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. *Microbiol Spectr* 2023; **11**(2): e0467422.
- 48. Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. *Int J Antimicrob Agents* 2021; **58**(5): 106428.
- 49. Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Brechot C. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. *EClinicalMedicine* 2022; **45**: 101310.

- 50. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *EClinicalMedicine* 2021; **37**: 100957.
- 51. Cairns DM, Dulko D, Griffiths JK, et al. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial. *JAMA Network Open* 2022; **5**(2): e2144942-e.
- 52. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. *JAMA* 2021; **326**(17): 1703-12.
- 53. Gonzalez-Ochoa AJ, Raffetto JD, Hernandez AG, et al. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. *Thromb Haemost* 2021; **121**(7): 944-54.
- 54. Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol* 2022; **9**(8): e594-e604.
- 55. Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol* 2022; **9**(8): e585-e93.
- 56. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA Intern Med* 2022; **182**(1): 42-9.
- 57. Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). *Clin Microbiol Infect* 2022; **28**(7): 1010-6.
- 58. Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**(2): e210369.
- 59. Adler UC, Adler MS, Padula AEM, et al. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). *J Integr Med* 2022; **20**(3): 221-9.
- 60. Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, et al. Efficacy of a multiple-indication antiviral herbal drug (Saliravira(R)) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. *Biomed Pharmacother* 2022; **149**: 112729.
- 61. Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. *Lancet Respir Med* 2021; **9**(10): 1130-40.
- 62. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. *JAMA* 2021; **326**(6): 490-8.
- 63. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). *Sci Rep* 2022; **12**(1): 10978.

- 64. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. *Clinical Infectious Diseases* 2020; **73**(11): e4073-e81.
- 65. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 2021; **9**(2): E693-E702.
- 66. Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *Eclinicalmedicine* 2021; **33**.